

REFINITIV

DELTA REPORT

10-Q

JYNT - JOINT CORP

10-Q - MARCH 31, 2024 COMPARED TO 10-Q - SEPTEMBER 30, 2023

The following comparison report has been automatically generated

TOTAL DELTAS 1267

█ CHANGES 226

█ DELETIONS 633

█ ADDITIONS 408

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934

For the quarterly period ended **September 30, 2023** **March 31, 2024**

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934

OR

For the transition period from _____ to _____

Commission file number: 001-36724

The Joint Corp.

(Exact name of registrant as specified in its charter)

Delaware

90-0544160

(State or other jurisdiction of incorporation or organization)

(IRS Employer Identification No.)

16767 N. Perimeter Drive, Suite 110, Scottsdale

Arizona

85260

(Address of principal executive offices)

(Zip Code)

(480) 245-5960

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.001 Par Value Per Share	JYNT	The Nasdaq Capital Market LLC

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (\$232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act:

Large accelerated filer

Accelerated filer

Non- accelerated filer

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell Company (as defined in Rule 12b-2 of the Exchange Act). Yes No

As of November 6, 2023 May 1, 2024, the registrant had 14,754,287 14,973,910 shares of Common Stock (\$0.001 par value) outstanding.

[Table of](#) [Contents](#)

THE JOINT CORP.
FORM 10-Q

TABLE OF CONTENTS

		PAGE NO.
<u>PART I FINANCIAL INFORMATION</u>		
<u>Item 1.</u>	<u>Financial Statements:</u>	
	Condensed Consolidated Balance Sheets as of September 30, 2023 March 31, 2024 (audited) and December 31, 2022 2023	1
	Condensed Consolidated Income Statements for the Three and Nine Months Ended September 30, 2023 March 31, 2024 and 2022 2023 (audited)	3
	Condensed Consolidated Statements of Changes in Stockholders' Equity for the Nine Three Months Ended September 30, 2023 March 31, 2024 and 2022 2023 (audited)	4
	Condensed Consolidated Statements of Cash Flows for the Nine Three Months Ended September 30, 2023 March 31, 2024 and 2022 2023 (audited)	55
	Notes to Unaudited Condensed Consolidated Financial Statements	57
<u>Item 2.</u>	<u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	31 24
<u>Item 3.</u>	<u>Quantitative and Qualitative Disclosures About Market Risk</u>	44 33
<u>Item 4.</u>	<u>Controls and Procedures</u>	44 33
<u>PART II OTHER INFORMATION</u>		
<u>Item 1.</u>	<u>Legal Proceedings</u>	45 34
<u>Item 1A.</u>	<u>Risk Factors</u>	45 34
<u>Item 2.</u>	<u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	47 34
<u>Item 3.</u>	<u>Other Information</u>	47
<u>Item 6.</u>	<u>Exhibits</u>	48 35
<u>SIGNATURES</u>		
		49 36

[Table of](#) [Contents](#)

PART I: FINANCIAL INFORMATION

ITEM 1. UNAUDITED FINANCIAL STATEMENTS

THE JOINT CORP. AND SUBSIDIARY AND AFFILIATES
CONDENSED CONSOLIDATED BALANCE SHEETS

September 30, 2023	December 31, 2022	March 31, 2024	March 31, 2024	December 31, 2023

ASSETS	ASSETS	(unaudited)	(as restated)
Current assets:	Current assets:		
Current assets:			
Current assets:			
Cash and cash equivalents	Cash and cash equivalents		
Cash and cash equivalents			
Cash and cash equivalents			
Cash and cash equivalents	Cash and cash equivalents	\$ 16,050,137	\$ 9,745,066
Restricted cash	Restricted cash	1,092,216	805,351
Accounts receivable, net	Accounts receivable, net	3,653,127	3,911,272
Deferred franchise and regional development costs, current portion	Deferred franchise and regional development costs, current portion	1,054,534	1,054,060
Prepaid expenses and other current assets	Prepaid expenses and other current assets	2,602,563	2,098,359
Assets held for sale	Assets held for sale	3,972,113	—
Total current assets	Total current assets	28,424,690	17,614,108
Property and equipment, net	Property and equipment, net	15,355,755	17,475,152
Operating lease right-of-use asset	Operating lease right-of-use asset	19,803,896	20,587,199
Deferred franchise and regional development costs, net of current portion	Deferred franchise and regional development costs, net of current portion	5,409,924	5,707,678
Intangible assets, net	Intangible assets, net	8,623,115	10,928,295
Goodwill	Goodwill	8,448,893	8,493,407
Deferred tax assets (\$1.0 million and \$1.0 million attributable to VIEs)	Deferred tax assets (\$1.0 million and \$1.0 million attributable to VIEs)	11,741,090	11,928,152
Deferred tax assets (\$1.1 million and \$1.1 million attributable to VIEs as of March 31, 2024 and December 31, 2023)			
Deposits and other assets	Deposits and other assets	765,263	756,386
Total assets	Total assets	\$ 98,572,626	\$ 93,490,377
LIABILITIES AND STOCKHOLDERS' EQUITY	LIABILITIES AND STOCKHOLDERS' EQUITY		
LIABILITIES AND STOCKHOLDERS' EQUITY			
LIABILITIES AND STOCKHOLDERS' EQUITY			

Current liabilities:	Current liabilities:	
Current liabilities:		
Current liabilities:		
Accounts payable		
Accounts payable	Accounts payable	
Accounts payable	\$ 1,877,162	\$ 2,966,589
Accrued expenses	Accrued expenses	
Co-op funds liability	Co-op funds liability	
Payroll liabilities (\$1.0 million and \$0.6 million attributable to VIE)	3,875,453	2,030,510
Payroll liabilities (\$1.0 million and \$0.7 million attributable to VIEs as of March 31, 2024 and December 31, 2023)		
Operating lease liability, current portion	Operating lease liability, current portion	
Finance lease liability, current portion	Finance lease liability, current portion	
Deferred franchise revenue, current portion	2,512,350	2,468,601
Deferred revenue from company clinics (\$4.6 million and \$4.7 million attributable to VIE)	6,538,713	7,471,549
Deferred franchise fee revenue, current portion		
Deferred revenue from company clinics (\$1.6 million and \$1.6 million attributable to VIEs as of March 31, 2024 and December 31, 2023)		
Upfront regional developer fees, current portion	Upfront regional developer fees, current portion	
Other current liabilities	Other current liabilities	
Liabilities to be disposed of	2,971,933	—

Liabilities to be disposed of (\$3.7 million and \$3.6 million attributable to VIEs as of March 31, 2024 and December 31, 2023)			
Total current liabilities	Total current liabilities	27,674,539	23,217,017
Operating lease liability, net of current portion	Operating lease liability, net of current portion	17,200,146	18,672,719
Finance lease liability, net of current portion	Finance lease liability, net of current portion	44,490	63,507
Debt under the Credit Agreement	Debt under the Credit Agreement	2,000,000	2,000,000
Deferred franchise revenue, net of current portion		13,980,758	14,161,134
Deferred franchise fee revenue, net of current portion			
Upfront regional developer fees, net of current portion	Upfront regional developer fees, net of current portion	1,099,718	1,500,278
Other liabilities (\$1.3 million and \$1.3 million attributable to VIE)		1,287,880	1,287,879
Total liabilities		63,287,531	60,902,534
Commitments and contingencies (Note 10)			
Stockholders' equity:			
Series A preferred stock, \$0.001 par value; 50,000 shares authorized, 0 issued and outstanding, as of September 30, 2023 and December 31, 2022		—	—

[Table of Contents](#)

Common stock, \$0.001 par value; 20,000,000 shares authorized, 14,786,411 shares issued and 14,754,287 shares outstanding as of September 30, 2023 and 14,560,353 shares issued and 14,528,487 outstanding as of December 31, 2022	14,786	14,560
--	--------	--------

Other
liabilities (\$1.2
million and
\$1.2 million
attributable to
VIE as of
March 31,
2024 and
December 31,
2023)

Total
liabilities

Commitments
and
contingencies
(Note 10)

Commitments and contingencies (Note 10)

Stockholders'
equity:

Series A preferred stock,
\$0.001 par value; 50,000
shares authorized, 0 issued
and outstanding, as of March
31, 2024 and December 31,
2023

Series A preferred stock,
\$0.001 par value; 50,000
shares authorized, 0 issued
and outstanding, as of March
31, 2024 and December 31,
2023

Series A preferred stock,
\$0.001 par value; 50,000
shares authorized, 0 issued
and outstanding, as of March
31, 2024 and December 31,
2023

Common
stock, \$0.001
par value;
20,000,000
shares
authorized,
14,968,547
shares issued
and
14,935,716
shares
outstanding
as of March
31, 2024 and
14,783,757
shares issued
and
14,751,633
outstanding
as of
December 31,
2023

Additional paid-	Additional paid-
in capital	in capital
	46,969,761
Treasury stock	45,558,305
32,124 shares as of September 30, 2023 and 31,866 shares as of December 31, 2022, at cost	(860,474)
	(856,642)

Treasury stock				
32,831				
shares as of March 31, 2024				
and				
32,124				
shares as of December 31, 2023,				
at cost				
Accumulated deficit	Accumulated deficit	(10,863,978)	(12,153,380)	
Total The Joint Corp. stockholders' equity	Total The Joint Corp. stockholders' equity	35,260,095	32,562,843	
Non-controlling interest		25,000	25,000	
Non-controlling Interest				
Total equity	Total equity	35,285,095	32,587,843	
Total liabilities and stockholders' equity	Total liabilities and stockholders' equity	\$98,572,626	\$93,490,377	

The accompanying notes are an integral part of these condensed consolidated financial statements.

[Table of Contents](#)

THE JOINT CORP. AND SUBSIDIARY AND AFFILIATES
CONDENSED CONSOLIDATED INCOME STATEMENTS
(unaudited)

	Three Months Ended		Nine Months Ended	
	September 30,		September 30,	
	2023	2022	2023	2022
	(as restated)		(as restated)	
Revenues:				
Revenues from company-owned or managed clinics	\$ 17,882,303	\$ 15,836,327	\$ 52,813,098	\$ 42,936,298
Royalty fees	7,143,791	6,604,653	21,181,973	19,024,799
Franchise fees	754,029	642,405	2,179,822	1,970,256
Advertising fund revenue	2,050,106	1,881,367	6,043,563	5,417,840
Software fees	1,301,577	1,109,753	3,746,394	3,166,732
Other revenues	342,143	375,314	1,117,103	1,058,008
Total revenues	29,473,949	26,449,819	87,081,953	73,573,933
Cost of revenues:				
Franchise and regional development cost of revenues	2,228,689	1,988,764	6,605,964	5,694,723
IT cost of revenues	375,411	348,331	1,068,332	1,010,446
Total cost of revenues	2,604,100	2,337,095	7,674,296	6,705,169
Selling and marketing expenses	4,301,017	3,539,287	13,169,079	10,666,500
Depreciation and amortization	2,349,206	1,779,924	6,893,529	4,578,450
General and administrative expenses	20,212,750	17,796,806	60,156,022	51,900,533

Total selling, general and administrative expenses	26,862,973	23,116,017	80,218,630	67,145,483
Net loss on disposition or impairment	904,923	264,391	1,114,738	360,140
Income (loss) from operations	(898,047)	732,316	(1,925,711)	(636,859)
Other income (expense), net	(6,244)	(25,235)	3,708,399	(60,668)
Income (loss) before income tax (benefit) expense	(904,291)	707,081	1,782,688	(697,527)
Income tax (benefit) expense	(188,018)	(24,015)	493,286	(560,976)
Net (loss) income	\$ (716,273)	\$ 731,096	\$ 1,289,402	\$ (136,551)
Earnings per share:				
Basic earnings (loss) per share	\$ (0.05)	\$ 0.05	\$ 0.09	\$ (0.01)
Diluted earnings (loss) per share	\$ (0.05)	\$ 0.05	\$ 0.09	\$ (0.01)
Basic weighted average shares	14,790,663	14,512,856	14,666,222	14,474,323
Diluted weighted average shares	15,015,953	14,829,629	14,931,474	15,119,264

	Three Months Ended March 31,	
	2024	2023
Revenues:		
Revenues from company-owned or managed clinics	\$ 17,537,504	\$ 17,127,957
Royalty fees	7,587,547	6,866,023
Franchise fees	655,873	754,425
Advertising fund revenue	2,166,473	1,952,406
Software fees	1,386,776	1,210,005
Other revenues	387,993	390,004
Total revenues	29,722,166	28,300,820
Cost of revenues:		
Franchise and regional development cost of revenues	2,341,765	2,140,835
IT cost of revenues	374,311	333,850
Total cost of revenues	2,716,076	2,474,685
Selling and marketing expenses	3,886,113	4,160,244
Depreciation and amortization	1,403,906	2,215,055
General and administrative expenses	20,263,692	20,038,476
Total selling, general and administrative expenses	25,553,711	26,413,775
Net loss on disposition or impairment	362,103	65,469
Income (loss) from operations	1,090,276	(653,109)
Other income, net	35,630	3,821,162
Income before income tax expense	1,125,906	3,168,053
Income tax expense	178,927	841,889
Net income	\$ 946,979	\$ 2,326,164
Earnings per share:		
Basic earnings per share	\$ 0.06	\$ 0.16
Diluted earnings per share	\$ 0.06	\$ 0.16
Basic weighted average shares	14,801,354	14,566,185
Diluted weighted average shares	15,011,286	14,861,734

The accompanying notes are an integral part of these condensed consolidated financial statements.

[Table of Contents](#)

THE JOINT CORP. AND SUBSIDIARY AND AFFILIATES

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY
(unaudited)

		Common Stock		Additional Paid In Capital		Treasury Stock		Accumulated Deficit	Joint Corp. equity	Non-controlling interest	Total	Common Stock		Additional Paid In Capital		Treasury Stock		Accumulated Deficit	Joint Corp. equity	Non-controlling interest	Total
Balances, December 31, 2022, as restated		14,560,353	\$14,560	\$45,558,305	31,866	(\$856,642)	(\$12,153,380)	\$32,562,843	\$25,000	\$32,587,843											
Balances, December 31, 2023																					
Balances, December 31, 2023																					
Balances, December 31, 2023																					
Stock-based compensation expense	Stock-based compensation expense	—	—	266,210	—	—	—	—	266,210	—	266,210										
Issuance of restricted stock	Issuance of restricted stock	95,386	95	(95)	—	—	—	—	—	—	—										
Exercise of stock options	Exercise of stock options	15,621	16	138,441	—	—	—	—	138,457	—	138,457										
Purchases of treasury stock under employee stock plans	Purchases of treasury stock under employee stock plans	—	—	—	169	(2,637)	—	—	(2,637)	—	(2,637)										
Net Income		—	—	—	—	—	2,326,164	2,326,164	2,326,164	—	2,326,164										
Balances, March 31, 2023, as revised (audited)		14,671,360	\$14,671	\$45,962,861	32,035	(\$859,279)	\$ (9,827,216)	\$35,291,037	\$25,000	\$35,316,037											
Stock-based compensation expense		—	—	417,017	—	—	—	—	417,017	—	417,017										
Issuance of restricted stock		91,158	91	(91)	—	—	—	—	—	—	—										
Exercise of stock options		10,002	10	63,919	—	—	—	—	63,929	—	63,929										
Net loss		—	—	—	—	—	(320,489)	(320,489)	—	—	(320,489)										
Balances, June 30, 2023 (audited)		14,772,520	\$14,772	\$46,443,706	32,035	(\$859,279)	\$ (10,147,705)	\$35,451,494	\$25,000	\$35,476,494											
Stock-based compensation expense		—	—	526,069	—	—	—	—	526,069	—	526,069										
Issuance of restricted stock		13,891	14	(14)	—	—	—	—	—	—	—										
Exercise of stock options		—	—	—	—	—	—	—	—	—	—										
Purchases of treasury stock under employee stock plans		—	—	—	89	(1,195)	—	(1,195)	—	(1,195)	—	(1,195)									
Net loss		—	—	—	—	—	(716,273)	(716,273)	—	—	(716,273)										
Balances, September 30, 2023 (audited)		14,786,411	\$14,786	\$46,969,761	32,124	(\$860,474)	\$ (10,863,978)	\$35,260,095	\$25,000	\$35,285,095											
Net income																					
Balances, March 31, 2024 (audited)																					

[Table of Contents](#)

		Common Stock		Additional Paid In Capital		Treasury Stock		Accumulated Deficit (as restated)	Joint Corp. stockholders' equity (as restated)	Total The Non-controlling interest (as restated)	Total
		Shares	Amount	Shares	Amount	Shares	Amount				
Balances, December 31,											
2021, as restated		14,451,355	\$14,450	\$43,900,157		31,643		\$(850,838)	\$(12,780,085)	\$30,283,684	\$ 25,000 \$30,308,684
Common Stock											
	Shares			Shares		Shares					
	Shares			Shares		Shares					
	Shares			Shares		Shares					
Balances,											
December 31,											
2022											
Stock-based compensation expense	Stock-based compensation expense	—	—	323,556		—	—	—	323,556	—	323,556
Issuance of restricted stock	Issuance of restricted stock	36,722	37	(37)		—	—	—	—	—	—
Exercise of stock options	Exercise of stock options	4,972	5	49,618		—	—	—	49,623	—	49,623
Purchases of treasury stock under employee stock plans	Purchases of treasury stock under employee stock plans	—	—	—		74	(2,598)	—	(2,598)	—	(2,598)
Net income		—	—	—		—	—	4,220	4,220	—	4,220
Balances, March 31, 2022, as restated (unaudited)											
14,493,049	\$14,492	\$44,273,294		31,717		\$(853,436)	\$(12,775,865)	\$30,658,485	\$ 25,000	\$30,683,485	
Stock-based compensation expense											
Issuance of restricted stock	340,191	—	—	—	—	—	—	340,191	—	340,191	
Exercise of stock options	28,758	29	(29)	—	—	—	—	—	—	—	—
Net loss	64,045	—	—	—	—	—	—	64,050	—	64,050	
Exercise of stock options	4,610	5	64,045	—	—	—	—	—	—	—	—
Net loss	—	—	—	—	—	—	(871,867)	(871,867)	—	—	(871,867)
Balances, June 30, 2022, as restated (unaudited)											
14,526,417	\$14,526	\$44,677,501		31,717		\$(853,436)	\$(13,647,732)	\$30,190,859	\$ 25,000	\$30,215,859	
Stock-based compensation expense											
Issuance of restricted stock	305,815	—	—	—	—	—	—	305,815	—	305,815	
Exercise of stock options	2,845	3	(3)	—	—	—	—	—	—	—	—
Exercise of stock options	248,324	—	—	—	—	—	—	248,356	—	248,356	
Purchases of treasury stock under employee stock plans	—	—	—	149		(3,206)	—	(3,206)	—	—	(3,206)
Change in redemption value of non-controlling interest	—	—	—	—	—	—	—	—	—	—	—
Net income	—	—	—	—	—	—	731,096	731,096	—	—	731,096
Balances, September 30, 2022, as restated (unaudited)											
14,561,545	\$14,561	\$45,231,637		31,866		\$(856,642)	\$(12,916,636)	\$31,472,920	\$ 25,000	\$31,497,920	
Net Income											
Balances, March 31, 2023 (unaudited)											

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

THE JOINT CORP. AND SUBSIDIARY AND AFFILIATES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)

		Nine Months Ended September 30,			
		2023	2022		
Three Months Ended March 31,				Three Months Ended March 31,	
2024		2024		2023	
Cash flows from operating activities:		Cash flows from operating activities:			
Net income (loss)		\$ 1,289,402	\$ (136,551)		
Adjustments to reconcile net income (loss) to net cash provided by operating activities:					
Cash flows from operating activities:					
Cash flows from operating activities:					
Net income					
Net income					
Net income					
Adjustments to reconcile net income to net cash provided by operating activities:					
Depreciation and amortization		Depreciation and amortization			
Net loss on disposition or impairment		6,893,529	4,578,450		
Depreciation and amortization					
Depreciation and amortization					
Net loss on disposition or impairment (non-cash portion)		1,114,738	360,140		

Net franchise fees recognized upon termination of franchise agreements	Net franchise fees recognized upon termination of franchise agreements	(170,720)	(15,218)
Deferred income taxes	Deferred income taxes	187,062	(961,759)
Stock-based compensation expense		1,209,296	969,562
Changes in operating assets and liabilities, net of acquisitions:			
Stock based compensation expense			
Changes in operating assets and liabilities:			
Accounts receivable			
Accounts receivable			
Accounts receivable	Accounts receivable	258,145	(244,236)
Prepaid expenses and other current assets	Prepaid expenses and other current assets	(504,203)	(450,702)
Deferred franchise costs	Deferred franchise costs	166,078	(186,618)
Deposits and other assets	Deposits and other assets	(15,377)	(153,650)
Assets and liabilities held for sale, net			
Accounts payable	Accounts payable	(1,244,767)	50,702
Accrued expenses	Accrued expenses	1,279,949	(571,447)
Payroll liabilities	Payroll liabilities	1,844,943	(1,118,259)
Deferred revenue	Deferred revenue	(551,226)	1,161,393
Upfront regional developer fees	Upfront regional developer fees	(496,730)	(977,841)
Other liabilities	Other liabilities	34,638	728,449

Net cash provided by operating activities	Net cash provided by operating activities	11,294,757	3,032,415
Cash flows from investing activities:	Cash flows from investing activities:		
Acquisition of AZ clinics	—	(6,861,256)	
Acquisition of NC clinics	—	(1,105,000)	
Acquisition of CA clinics	(1,050,000)	—	
Cash flows from investing activities:			
Cash flows from investing activities:			
Proceeds from sale of clinics			
Proceeds from sale of clinics			
Proceeds from sale of clinics			
Purchase of property and equipment	Purchase of property and equipment	(3,833,148)	(4,322,673)
Net cash used in investing activities	Net cash used in investing activities	(4,883,148)	(12,288,929)
Cash flows from financing activities:	Cash flows from financing activities:		
Cash flows from financing activities:			
Payments of finance lease obligation			
Payments of finance lease obligation			
Payments of finance lease obligation	Payments of finance lease obligation	(18,227)	(43,907)
Purchases of treasury stock under employee stock plans	Purchases of treasury stock under employee stock plans	(3,832)	(5,804)
Proceeds from exercise of stock options	Proceeds from exercise of stock options	202,386	362,029
Repayment of debt under the Paycheck Protection Program	—	—	

Net cash provided by financing activities	180,327	312,318
Repayment of debt under the Credit Agreement		
Net cash provided by (used in) financing activities		
Increase (decrease) in cash, cash equivalents and restricted cash	6,591,936	(8,944,196)
Increase in cash, cash equivalents and restricted cash		
Increase in cash, cash equivalents and restricted cash		
Increase in cash, cash equivalents and restricted cash		
Cash, cash equivalents and restricted cash, beginning of period	10,550,417	19,912,338
Cash, cash equivalents and restricted cash, end of period	\$17,142,353	\$10,968,142
Reconciliation of cash, cash equivalents and restricted cash: September 30, 2023	September 30, 2022	
Reconciliation of cash, cash equivalents and restricted cash:		
Cash and cash equivalents	\$16,050,137	\$10,272,112
Restricted cash	1,092,216	696,030
	\$17,142,353	\$10,968,142
\$		

[Table of Contents](#)

Supplemental cash flow disclosures:

The following table represents supplemental cash flow disclosures and non-cash investing and financing activities:

	Nine Months Ended September 30,		2022
	2023	2024	
Net cash paid for:			
Interest			
Interest			
Interest	Interest	\$ 163,334	\$ 43,938
Income taxes	Income taxes	\$ 468,289	\$ 69,274
Income taxes			
Income taxes			
Non-cash investing and financing activity:			
Non-cash investing and financing activity:			
Non-cash investing and financing activity:	Non-cash investing and financing activity:		
Unpaid purchases of property and equipment	Unpaid purchases of property and equipment	\$ 155,340	\$ 225,967
Non-cash investment in acquisition of franchised clinics		\$ 28,997	\$ 115,372
Unpaid purchases of property and equipment			
Unpaid purchases of property and equipment			

The accompanying notes are an integral part of these condensed consolidated financial statements.

[Table of Contents](#)

THE JOINT CORP. AND SUBSIDIARY AND AFFILIATES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Note 1: Nature of Operations and Summary of Significant Accounting Policies

Basis of Presentation

These unaudited financial statements represent the condensed consolidated financial statements of The Joint Corp. ("The Joint"), which includes its variable interest entities ("VIEs"), and its wholly owned subsidiary, The Joint Corporate Unit No. 1, LLC (collectively, the "Company"). The accompanying unaudited condensed consolidated **interim** financial statements reflect all adjustments which are necessary for a fair statement of the financial position, results of operations and cash flows for the periods presented in accordance with U.S. generally accepted accounting principles ("GAAP"). Such unaudited condensed consolidated **interim** financial statements have been prepared in accordance with the instructions to Form 10-Q pursuant to the rules and regulations of the Securities and Exchange Commission (the "SEC"). Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These unaudited condensed consolidated **interim** financial statements should be read in conjunction with The Joint Corp. and Subsidiary and Affiliates consolidated financial statements and the notes thereto as

set forth in The Joint's **Amended** Annual Report on Form **10-K/A** **10-K** as of and for the year ended **December 31, 2022** **December 31, 2023**, filed with the SEC on **September 26, 2023** ("Form **10-K/A**") **March 8, 2024**, which included all disclosures required by GAAP. The results of operations for the periods ended **September 30, 2023** **March 31, 2024** and **2022** **2023** are not necessarily indicative of expected operating results for the full year. The information presented throughout the document as of and for the three and nine-month periods ended **September 30, 2023** **March 31, 2024** and **2022** **2023** is unaudited.

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amount of assets, liabilities, revenue, costs, expenses and other (expenses) income that are reported in the condensed consolidated financial statements and accompanying disclosures. These estimates are based on management's best knowledge of current events, historical experience, actions that the Company may undertake in the future and on various other assumptions that are believed to be reasonable under the circumstances. As a result, actual results may be different from these estimates. For a discussion of significant estimates and judgments made in recognizing revenue, accounting for leases, and accounting for income taxes, see **this Note 1, Nature of Operations and Summary of Significant Accounting Policies**.

Principles of Consolidation

The accompanying condensed consolidated financial statements include the accounts of The Joint and its wholly owned subsidiary, The Joint Corporate Unit No. 1, LLC, which was dormant for all periods presented. The Company consolidates VIEs in which the Company is the primary beneficiary in accordance with Accounting Standards Codification 810, *Consolidations* ("ASC 810"). Non-controlling interests represent third-party equity ownership interests in VIEs. All significant inter-affiliate accounts and transactions between The Joint and its VIEs have been eliminated in consolidation.

Comprehensive Income

Net income was the same as comprehensive income for the three and nine months ended **September 30, 2023** **March 31, 2024** and **2022**.

Restatement of Previously Issued Interim Condensed Financial Statements (Unaudited and Restated)

Subsequent to the issuance of the Company's consolidated financial statements as of and for the year ended December 31, 2022, included in the Company's Annual Report on Form 10-K filed with the SEC on March 10, 2023, the following errors were identified:

- The Company has historically recorded the re-acquired Regional Developer Rights as an intangible asset and amortized the re-acquired Regional Developer Rights over the contractual terms under the RD Agreement remaining at the time of the re-acquisition. The Company has concluded that this treatment was incorrect in accordance with U.S. GAAP. The Company should not have capitalized the re-acquired Regional Developer Rights but instead should have recognized the full cost of the re-acquisition as an expense in the respective period.
- The Company has historically recorded the upfront fee paid by the regional developer as a deferred liability, which was then recognized ratably to revenue as the regional developer performed various service obligations. However, the

Table of Contents

Company concluded that the deferred liability should be ratably recognized against cost of revenue as an offset against future commissions instead of revenue.

- The Company has historically charged the VIEs a management fee for the benefit of the Company providing non-clinical administrative services needed by the professional corporation chiropractic practice. The economic compensation or profitability resulting from an intercompany transaction between two or more parties is based on each party's relative contribution to the economic activity under analysis. The standalone professional corporations have not historically been profitable from an income tax perspective and are fully valuing their deferred tax assets and related attributes for ASC 740 purposes. The professional corporations' earned annual losses were not consistent with their function, risk and asset profile for transfer pricing. As such, the Company has estimated transfer pricing adjustments, which were computed based on assumed targets of profitability. The resulting operating profit, after incorporating estimated transfer pricing adjustments, were further used as a means for computing overall potential tax exposure and correlative benefit.

The Company assessed the impact of these errors on its previously issued interim financial statements and determined them to be quantitatively and qualitatively material to the period ended September 30, 2022 based on its analysis of Staff Accounting Bulletin ("SAB") No. 99, "Materiality," and SAB No. 108, "Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements". These errors have been corrected in the consolidated balance sheets as of December 31, 2022 and 2021 and the consolidated income statements, statements of changes in stockholders' equity and statements of cash flows for the years then ended.

The following table summarizes the effect of the errors on the Company's condensed balance sheet as of September 30, 2022:

	September 30, 2022		September 30, 2022	
	As Previously Reported		Adjustments	
Intangible assets, net	\$ 10,162,506		\$ (2,124,740)	\$ 8,037,766
Deferred tax assets	9,115,231		3,333,327	12,448,558
Total assets	88,291,398		1,208,587	89,499,985
Current liabilities:				
Deferred franchise and regional development fee revenue, current portion	2,974,993		(2,974,993)	—
Deferred franchise fee revenue, current portion	—		2,410,951	2,410,951

Upfront regional developer fees, current portion	—	564,042	564,042
Other current liabilities	522,500	73,533	596,033
Total current liabilities	21,637,706	73,533	21,711,239
Deferred franchise and regional development fee revenue, net of current portion	15,604,180	(15,604,180)	—
Deferred franchise fee revenue, net of current portion	—	13,870,401	13,870,401
Upfront regional developer fees, net of current portion	—	1,733,779	1,733,779
Other liabilities	27,230	1,162,607	1,189,837
Total liabilities	56,765,925	1,236,140	58,002,065
Accumulated deficit	(12,889,083)	(27,553)	(12,916,636)
Total The Joint Corp. stockholders' equity	31,500,473	(27,553)	31,472,920
Total equity	31,525,473	(27,553)	31,497,920
Total liabilities and stockholders' equity	88,291,398	1,208,587	89,499,985

The following table summarizes the effect of the errors on the Company's condensed income statement for the three and nine months ended September 30, 2022:

[Table of Contents](#)

	As Previously Reported		Adjustments		As Restated	
	Three Months Ended September 30, 2022	Nine Months Ended September 30, 2022	Three Months Ended September 30, 2022	Nine Months Ended September 30, 2022	Three Months Ended September 30, 2022	Nine Months Ended September 30, 2022
Revenues:						
Regional developer fees	\$ 153,181	\$ 524,923	\$ (153,181)	\$ (524,923)	\$ —	\$ —
Total revenues	26,603,000	74,098,856	(153,181)	(524,923)	26,449,819	73,573,933
Cost of revenues:						
Franchise and regional developer cost of revenues	2,141,945	6,219,646	(153,181)	(524,923)	1,988,764	5,694,723
Total cost of revenues	2,490,276	7,230,092	(153,181)	(524,923)	2,337,095	6,705,169
Depreciation and amortization	2,011,768	5,341,420	(231,844)	(762,970)	1,779,924	4,578,450
General and administrative expenses	17,796,806	49,703,451	—	2,197,082	17,796,806	51,900,533
Total selling, general and administrative expenses	23,347,861	65,711,371	(231,844)	1,434,112	23,116,017	67,145,483
Income (loss) from operations	500,472	797,253	231,844	(1,434,112)	732,316	(636,859)
Income before income tax expense (benefit)	475,237	736,585	231,844	(1,434,112)	707,081	(697,527)
Income tax expense (benefit)	(15,876)	106,527	(8,139)	(667,503)	(24,015)	(560,976)
Net income (loss)	\$ 491,113	\$ 630,058	\$ 239,983	\$ (766,609)	\$ 731,096	\$ (136,551)
Earnings per share:						
Basic earnings (loss) per share	\$ 0.03	\$ 0.04	\$ 0.02	\$ (0.05)	\$ 0.05	\$ (0.01)
Diluted earnings (loss) per share	\$ 0.03	\$ 0.04	\$ 0.02	\$ (0.05)	\$ 0.05	\$ (0.01)

The following table summarizes the effect of the errors on the Company's condensed statements of stockholders' equity as of September 30, 2022, June 30, 2022, March 31, 2022 and December 31, 2021:

	Accumulated Deficit		Total The Joint Corp. Stockholder's Equity		Total Equity
	\$	(13,519,142)	\$	29,544,627	\$ 29,569,627
Balances, December 31, 2021 (as previously reported)	\$	739,057	\$	739,057	\$ 739,057
Adjustment due to cumulative error correction	\$	(12,780,085)	\$	30,283,684	\$ 30,308,684
Balances, December 31, 2021 (as restated)	\$	(13,724,938)	\$	29,709,412	\$ 29,734,412
Balances, March 31, 2022 (as previously reported)	\$	949,073	\$	949,073	\$ 949,073
Adjustment due to cumulative error correction	\$	(12,775,865)	\$	30,658,485	\$ 30,683,485
Balances, March 31, 2022 (as restated)	\$	(13,724,938)	\$	29,709,412	\$ 29,734,412

Balances, June 30, 2022 (as previously reported)	\$ (13,380,196)	\$ 30,458,395	\$ 30,483,395
Adjustment due to cumulative error correction	(267,537)	(267,537)	(267,537)
Balances, June 30, 2022 (as restated)	<u>\$ (13,647,733)</u>	<u>\$ 30,190,858</u>	<u>\$ 30,215,858</u>
Balances, September 30, 2022 (as previously reported)	\$ (12,889,083)	\$ 31,500,473	\$ 31,525,473
Adjustment due to cumulative error correction	(27,553)	(27,553)	(27,553)
Balances, September 30, 2022 (as restated)	<u>\$ (12,916,636)</u>	<u>\$ 31,472,920</u>	<u>\$ 31,497,920</u>

The following table summarizes the effect of the errors on the Company's condensed statement of cash flows for the nine-month period ended September 30, 2022:

[Table of Contents](#)

	Nine Months Ended September 30, 2022		Nine Months Ended September 30, 2022	
	As Previously Reported		Adjustments	As Restated
Cash flows from operating activities:				
Net income (loss)	\$ 630,058	(766,609)	\$ (136,551)	
Adjustments to reconcile net income (loss) to net cash provided by operating activities:				
Depreciation and amortization	5,341,420	(762,970)	4,578,450	
Deferred income taxes	73,403	(1,035,162)	(961,759)	
Changes in operating assets and liabilities:				
Upfront regional developer fees	—	(977,841)	(977,841)	
Deferred revenue	636,470	524,923	1,161,393	
Other liabilities	360,790	367,659	728,449	
Net cash provided by (used in) operating activities	5,682,415	(2,650,000)	3,032,415	
Cash flows from investing activities:				
Reacquisition and termination of regional developer rights	(2,650,000)	2,650,000	—	
Net cash used in investing activities	(14,938,929)	2,650,000	(12,288,929)	
Decrease in cash	(8,944,196)	—	(8,944,196)	

2023, respectively.

[Nature of Operations](#)

The Joint Corp., a Delaware corporation, was formed on March 10, 2010 for the principal purpose of franchising and developing chiropractic clinics, selling regional developer rights, supporting the operations of franchised chiropractic clinics, and operating and managing corporate chiropractic clinics at locations throughout the United States of America. The franchising of chiropractic clinics is regulated by the Federal Trade Commission and various state authorities.

[Table of Contents](#)

The following table summarizes the number of clinics in operation under franchise agreements and as company-owned or managed clinics for the three and nine months ended September 30, 2023 March 31, 2024 and 2022: 2023:

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2023	2022	2023	2022
Franchised clinics:				
Clinics open at beginning of period	756	662	712	610
Opened during the period	24	33	76	91
Acquired during the period	—	1	—	1
Sold during the period	—	(4)	(3)	(8)
Closed during the period	(2)	(2)	(7)	(4)
Clinics in operation at the end of the period	778	690	778	690

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2023	2022	2023	2022
Company-owned or managed clinics:				
Clinics open at beginning of period	134	107	126	96
Opened during the period	2	5	9	12
Acquired during the period	—	4	3	8
Sold during the period	—	(1)	—	(1)
Closed during the period	—	—	(2)	—
Clinics in operation at the end of the period	136	115	136	115
Total clinics in operation at the end of the period	914	805	914	805
Clinic licenses sold but not yet developed	155	212	155	212
Licenses for future clinics subject to executed letters of intent	42	40	42	40

[Table of Contents](#)

	Three Months Ended March 31,	
	2024	2023
Franchised clinics:		
Clinics open at beginning of period	800	712
Opened during the period	23	29
Acquired during the period	—	—
Sold during the period	—	—
Closed during the period	(4)	(1)
Clinics in operation at the end of the period	819	740
Three Months Ended March 31,		
	2024	2023
Company-owned or managed clinics:		
Clinics open at beginning of period	135	126
Opened during the period	—	4
Acquired during the period	—	—
Sold during the period	—	—
Closed during the period	—	—
Clinics in operation at the end of the period	135	130
Total clinics in operation at the end of the period	954	870
Clinic licenses sold but not yet developed	117	178
Future clinic licenses subject to executed letters of intent	46	39

Variable Interest Entities

Certain states prohibit the “corporate practice of chiropractic,” which restricts business corporations from practicing chiropractic care by exercising control over clinical decisions by chiropractic doctors. In states that prohibit the corporate practice of chiropractic, the Company typically enters into long-term management agreements with professional corporations (“PCs”) that are owned by licensed chiropractic doctors, which, in turn, employ or contract with doctors who provide professional chiropractic care in its clinics. Under these management agreements with PCs, the Company provides, on an exclusive basis, all non-clinical services of the chiropractic practice. The Company has entered into such management agreements with four PCs, including one in New Jersey, in connection with the opening of company-managed clinics in April 2023. PCs. If an entity is deemed to be the primary beneficiary of a VIE, the entity is required to consolidate the VIE in its financial statements. An entity is deemed to be the primary beneficiary of a VIE if it has both of the following characteristics: (a) the power to direct the activities of a VIE that most significantly impact the VIE's VIE's economic performance, and (b) the obligation to absorb the majority of losses of the VIE or the right to receive the majority of benefits from the VIE. In accordance with relevant accounting guidance, these PCs were determined to be VIEs, as fees paid by the PCs to the Company as its management service provider are considered variable interests because the fees do not meet all the following criteria: (1) The fees are compensation for services provided and are commensurate with the level of effort required to provide those services; (2) The decision maker or service provider

does not hold other interests in the VIE that individually, or in the aggregate, would absorb more than an insignificant amount of the VIE's expected losses or receive more than an insignificant amount of the VIE's expected residual returns; and (3) The service arrangement includes only terms, conditions, or amounts that are customarily present in arrangements for similar services negotiated at arm's length. Additionally, the Company has determined that it has the ability to direct the activities that most significantly impact the performance of these PCs and has an obligation to absorb losses or receive benefits which could potentially be significant to the PCs. Accordingly, the PCs are VIEs for which the Company is the primary beneficiary and are consolidated by the Company.

VIE total revenue and general administrative expenses for the three months ended March 31, 2024 and nine-months ended September 30, 2023 and 2022 were as follows:

[Table of Contents](#)

	Three Months Ended		Nine Months Ended			
	September 30,		September 30,			
	2023	2022	2023	2022		
	(as restated)		(as restated)			
	Three Months Ended		Three Months Ended			
	March 31,		March 31,			
	2024		2024		2023	
Revenues	Revenues	\$10,688,500	\$9,150,103	\$30,997,617	\$25,433,407	
General and administrative expenses	General and administrative expenses	4,525,305	4,079,552	13,614,211	11,212,760	

The carrying amount of the VIEs' assets and liabilities was immaterial as of September 30, 2023 March 31, 2024 and December 31, 2022 December 31, 2023, except for their payroll liability balances and amounts collected in advance for membership and wellness packages, which are recorded as deferred revenue. The VIEs' payroll liability and deferred revenue from company managed clinics the balances as of September 30, 2023 and December 31, 2022 were as follows:

	September December		
	30,	31,	
	2023	2022	
Deferred tax assets	March 31, 2024		March 31, 2024
Payroll liabilities	Payroll liabilities	\$ 952,854	\$ 586,960
Deferred revenue from company managed clinics	Deferred revenue from company managed clinics	4,553,228	4,702,044
Liabilities to be disposed of			
Other liabilities			

Cash and Cash Equivalents

The Company considers all highly liquid instruments purchased with a maturity of three months or less at the date of purchase to be cash equivalents. The Company continually monitors its positions with, and credit quality of, the financial institutions with which it invests. As of the balance sheet date and periodically throughout the period, the Company has maintained balances in various operating accounts in excess of federally insured limits. The Company has invested substantially all of its cash in short-term bank deposits. The Company had no cash equivalents as of September 30, 2023 March 31, 2024 and December 31, 2022 December 31, 2023.

Restricted Cash

Restricted cash relates to cash that franchisees and company-owned or managed clinics contribute to the Company's National Marketing Fund and cash that franchisees provide to various voluntary regional Co-Op Marketing Funds. Cash contributed by franchisees to the National Marketing Fund is to be used in accordance with the Company's Franchise Disclosure Document with a focus on regional and national marketing and advertising. While such cash balance is not legally segregated and restricted as to withdrawal or usage, the Company's accounting policy is to classify these funds as restricted cash.

Accounts Receivable

Accounts receivable primarily represents amounts due from franchisees for royalty fees. The Company records an allowance for credit losses as a reduction to its accounts receivables for amounts that the Company does not expect to recover. An allowance for credit losses is determined through assessments of collectability based on historical trends, the financial condition of the Company's franchisees, including any known or anticipated bankruptcies and an evaluation of current economic conditions, as well as the Company's expectations of conditions in the future. Actual losses ultimately could differ materially in the near term from the amounts estimated in determining the allowance. As of **September 30, 2023** **March 31, 2024** and **December 31, 2022** **December 31, 2023**, the Company had an allowance for doubtful accounts of \$0.

Property and Equipment

Property and equipment are stated at cost, or, for property acquired as part of franchise acquisitions, at fair value at the date of closing. Depreciation is computed using the straight-line method over estimated useful lives, which is generally three to ten years. Leasehold improvements are amortized using the straight-line method over the shorter of the lease term or the estimated useful lives of the assets. Maintenance and repairs are charged to expense as **incurred**; **major incurred**. **Major** renewals and improvements are capitalized. When items of property or equipment are sold or retired, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is included in income. The losses on disposed of or retired property or equipment were recorded in net loss on disposition or impairment of **\$68,200** **\$51,808** and **\$217,810** **\$65,469** for the three months ended **March 31, 2024** and nine-months ended **September 30, 2023**, respectively. The losses on disposed of or retired property or equipment were recorded in net loss on disposition or impairment of **\$23,554** and **\$119,303** for the three and nine-months ended **September 30, 2022**, respectively. **2023**, respectively

Leases

Table of Contents

The Company leases property and equipment under operating and finance leases. The Company leases its corporate office space and the space for each of the company-owned or managed clinics in the portfolio. The Company recognizes a right-of-use ("ROU") asset and lease liability for all leases. Certain leases include one or more renewal options, generally for the same period as the initial term of the lease. The exercise of lease renewal options is generally at the Company's sole discretion and, as such, the Company typically determines that exercise of these renewal options is not reasonably certain. As a result, the Company does not include the renewal option period in the expected lease term and the associated lease payments are not included in the measurement of the right-of-use asset and lease liability. When available, the Company uses the rate implicit in the lease to discount lease payments; however, the rate implicit in the lease is not readily determinable for substantially all of its leases. In such cases, the Company estimates its incremental borrowing rate as the interest rate it would pay to borrow an amount equal to the lease payments over a similar term, with similar collateral as in the lease and in a similar economic environment. The Company estimates these rates using available evidence such as rates imposed by third-party lenders to the Company in recent financings or observable risk-free interest rate and credit spreads for commercial debt of a similar duration, with credit spreads correlating to the Company's estimated creditworthiness.

For operating leases that include rent holidays and rent escalation clauses, the Company recognizes lease expense on a straight-line basis over the lease term from the date it takes possession of the leased property. Pre-opening costs are recorded as incurred in general and administrative expenses. Variable lease payments, such as percentage rentals based on location sales, periodic adjustments for inflation, reimbursement of real estate taxes, any variable common area maintenance and any other variable costs associated with the leased property are expensed as incurred and are also included in general and administrative expenses on the accompanying **condensed** consolidated income statements.

Long-Lived Assets

The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recovered. The Company looks primarily to estimated undiscounted future cash flows in its assessment of whether or not long-lived assets are recoverable. The Company records an impairment loss when the carrying amount of the asset is not recoverable and exceeds its fair value. During the three and nine months ended **September 30, 2023** **March 31, 2024**, intangible assets property and equipment, net related to a clinic planned for closure asset groups determined to not be recoverable with a total carrying amount of approximately **\$80,000** **\$0.9 million** was written down to **zero**. **\$0.7 million**. As a result, the Company recorded a **noncash** **non-cash** impairment loss of **approximately \$80,000** **\$0.1 million** during the three and nine months ended **September 30, 2023**. During the three and nine months ended **September 30, 2022**, an operating lease ROU asset related to a closed clinic with a total carrying amount of approximately **\$250,000** was written down to **zero**. As a result, the Company recorded a **noncash** impairment loss of approximately **\$250,000** during the three and nine months ended **September 30, 2022** **March 31, 2024**.

In connection with the planned sale of 16 company-owned and managed clinics, the Company reclassified **\$2,153,454** of property and equipment and **\$2,204,293** of ROU assets to Assets held for sale and reclassified **\$2,585,642** of ROU liability and **\$386,291** of deferred revenue from company clinics to Liabilities to be disposed of, in the consolidated balance sheet as of **September 30, 2023**. Long-lived assets that meet the criteria for the held for sale criteria designation are reported at the lower of their carrying value or fair value less estimated costs cost to sell. As a result of its evaluation of the Company recorded a valuation allowance recoverability of **\$756,228** and **\$816,429** to adjust the carrying value of the assets and liabilities held for sale relative to the agreed upon sales prices or the clinics estimated fair values, the Company recorded an estimated loss on disposal group to fair value less cost to sell during of **\$0.2 million** for the three and nine months ended **September 30, 2023**, respectively. **March 31, 2024** as Net loss on disposition or impairment in its condensed consolidated income statement and a valuation allowance included in assets held for sale on its condensed consolidated balance sheet.

Revenue Recognition

The Company generates revenue primarily through its company-owned and managed clinics and through royalties, franchise fees, advertising fund contributions, **IT related** **IT related** income and computer software fees from its franchisees.

Revenues from Company-Owned or Managed Clinics. The Company earns revenues from clinics that it owns and operates or manages throughout the United States. Revenues are recognized when services are performed. The Company offers a variety of membership and wellness packages, which feature discounted pricing as compared with its single-visit pricing. Amounts collected in advance for membership and wellness packages are recorded as deferred revenue and recognized when the service is performed. Any unused visits associated with monthly memberships are recognized on a month-to-month basis. The Company recognizes a contract liability (or a deferred revenue liability) related to the prepaid treatment plans for which the Company has an ongoing performance obligation. The Company derecognizes this contract liability and recognizes revenue, as the patient consumes

his or her visits related to the package and the Company transfers its services. If the Company determines that it is not subject to unclaimed property laws for the portion of wellness package that it does not expect to be redeemed (referred to as "breakage"), then it recognizes breakage revenue in proportion to the pattern of exercised rights by the patient.

Royalties and Advertising Fund Revenue. The Company collects royalties from its franchisees, as stipulated in the franchise agreement, equal to 7% of gross sales and a marketing and advertising fee currently equal to 2% of gross sales. Royalties,

[Table of Contents](#)

including franchisee contributions to advertising funds, are calculated as a percentage of clinic sales over the term of the franchise agreement. The revenue accounting standard provides an exception for the recognition of sales-based royalties promised in

[Table of Contents](#)

exchange for a license (which generally requires a reporting entity to estimate the amount of variable consideration to which it will be entitled in the transaction price). Franchise agreement royalties, inclusive of advertising fund contributions, represent sales-based royalties that are related entirely to the Company's performance obligation under the franchise agreement and therefore, such royalties are recognized as franchisee clinic level sales occur. Royalties are collected semi-monthly two working days after each sales period has ended.

Franchise Fees. The Company requires the entire non-refundable initial franchise fee to be paid upon execution of a franchise agreement, which typically has an initial term of ten years. Initial franchise fees are recognized ratably on a straight-line basis over the term of the franchise agreement. The Company's services under the franchise agreement include training of franchisees and staff, site selection, construction/vendor management and ongoing operations support. The Company provides no financing to franchisees and offers no guarantees on their behalf. The services provided by the Company are highly interrelated with the franchise license and as such are considered to represent a single performance obligation. Renewal franchise fees, as well as transfer fees, are also recognized as revenue on a straight-line basis over the term of the respective franchise agreement.

Software Fees. The Company collects a monthly fee from its franchisees for use of its proprietary chiropractic software, computer support and internet services support. These fees are recognized ratably on a straight-line basis over the term of the respective franchise agreement.

Capitalized Sales Commissions: Commissions. Sale Sales commissions earned by the regional developers and the Company's Company's sales force are considered incremental and recoverable costs of obtaining a franchise agreement with a franchisee. These costs are deferred and then amortized as the respective franchise fees are recognized ratably on a straight-line basis over the term of the franchise agreement.

Regional Developer Fees. Fees

The Company has a regional developer program where regional developers are granted an exclusive geographical territory and commit to a minimum development obligation within that defined territory. Regional developer fees paid to the Company are non-refundable and are amortized on a straight-line bases basis over the term of the regional developer agreement and recognized as a decrease to franchise cost of revenues.

In addition, regional developers receive fees that are funded by the initial franchise fees collected from franchisees upon the sale of franchises within their exclusive geographical territory and a royalty of 3% of sales generated by franchised clinics in within their exclusive geographical territory. Initial fees related to the sale of franchises within their exclusive geographical territory are initially deferred as deferred franchise costs and are recognized as an expense in franchise cost of revenues when the respective revenue is recognized, which is generally over the term of the related franchise agreement. Royalties of 3% of sales generated by franchised clinics in their regions are also recognized as franchise cost of revenues as franchisee clinic level sales occur. This 3% fee is funded by the 7% royalties collected from the franchisees in their regions. Certain regional developer agreements result in the regional developer acquiring the rights to existing royalty streams from clinics already open in the respective territory. In those instances, the revenue associated from the sale of the royalty stream is recognized over the remaining life of the respective franchise agreements. The Company did not enter into any new regional developer agreements during the nine three months ended September 30, 2023 March 31, 2024.

Regional Developer Rights Contract Termination Costs

From time to time, subject to the Company's strategy, regional developer rights are reacquired by the Company, resulting in a termination of the contract. The termination costs to reacquire the regional developer rights are recognized at fair value, less any unrecognized upfront regional developer fee liability balance, as a general and 2022, administrative expense in the period in which the contract is terminated in accordance with the contract terms.

Advertising Costs

Advertising costs are advertising and marketing expenses incurred by the Company, primarily through advertising funds. The Company expenses production costs of commercial advertising upon first airing and expenses the costs of communicating the advertising in the period in which the advertising occurs. Advertising expenses were \$1,796,865 \$1,754,065 and \$5,375,156 \$1,948,485 for the three and nine months ended September 30, 2023, respectively. Advertising expenses were \$1,444,783 March 31, 2024 and \$3,763,351 for the three and nine months ended September 30, 2022, 2023, respectively.

Income Taxes

[Table of Contents](#)

Income tax expense during interim periods is based on applying an estimated annual effective income tax rate to year-to-date pre-tax income, plus any significant unusual or infrequently occurring items **which** are recorded in the interim period. The computation of the annual estimated effective tax rate at each interim period requires certain estimates and significant judgment, including, but not limited to, the expected pre-tax income for the year and permanent differences. The accounting estimates used to compute the provision for income taxes may change as new events occur, more experience is obtained, additional information becomes known or as the tax environment changes.

Table of Contents

Earnings (Loss) per Common Share

Basic earnings per common share is computed by dividing the net income **(loss)** by the weighted-average number of common shares outstanding during the period. Diluted earnings per common share is computed by giving effect to all potentially dilutive common shares, including restricted stock and stock options.

		Three Months Ended March 31,		Three Months Ended March 31,		Three Months Ended March 31,	
		2024		2024		2024	
Net income							
Net income							
Net income							
	Three Months Ended September 30,			Nine Months Ended September 30,			
Weighted average common shares outstanding - basic							
		2023	2022		2023	2022	
Net (loss) income	\$	(716,273)	\$ 731,096	\$	1,289,402	\$ (136,551)	
Weighted average common shares outstanding - basic							
Weighted average common shares outstanding - basic							
Weighted average common shares outstanding - basic		14,790,663	14,512,856		14,666,222	14,474,323	
Effect of dilutive securities:		Effect of dilutive securities:					
Effect of dilutive securities:							
Unvested restricted stock and stock options							
Unvested restricted stock and stock options							
Unvested restricted stock and stock options		225,290		316,773		265,252	
Weighted average common shares outstanding - diluted							
Weighted average common shares outstanding - diluted		15,015,953		14,829,629		14,931,474	
Weighted average common shares outstanding - diluted							

Weighted average common shares outstanding - diluted								
Basic earnings (loss) per share	\$ (0.05)	\$ 0.05	\$ 0.09	\$ (0.01)				
Diluted earnings (loss) per share	\$ (0.05)	\$ 0.05	\$ 0.09	\$ (0.01)				
Basic earnings per share								
Basic earnings per share								
Basic earnings per share								
Diluted earnings per share								
Diluted earnings per share								
Diluted earnings per share								

The following common stock equivalents were excluded from the computation of diluted earnings per share for the periods presented because including them would have been antidilutive:

	Three Months Ended September 30,	Three Months Ended March 31,	Three Months Ended March 31,	Three Months Ended March 31,	Nine Months Ended September 30,
Weighted average dilutive securities:					
Weighted average dilutive securities:					
Weighted average dilutive securities:					
Weighted average dilutive securities:	Weighted average dilutive securities:	2023	2022	2023	2022
Restricted stocks	Restricted stocks	—	—	—	—
Restricted stocks	Restricted stocks				
Stock options	Stock options	121,699	77,485	89,883	41,293
Stock options	Stock options				
Stock options	Stock options				

Stock-Based Compensation

The Company accounts for share-based payments by recognizing compensation expense based upon the estimated fair value of the awards on the date of grant. The Company determines the estimated grant-date fair value of restricted shares using the closing price on the date of the grant and the grant-date fair value of stock options using the Black-Scholes-Merton model. In order to calculate the fair value of the options, certain assumptions are made regarding the components of the model, including risk-free interest rate, volatility, expected dividend yield and expected option life. Changes to the assumptions could cause significant adjustments to the valuation. The Company recognizes compensation costs ratably over the period of service using the straight-line method. Forfeitures are estimated based on historical and forecasted turnover, which is approximately 5%.

Loss Contingencies

ASC Topic 450 governs the disclosure of loss contingencies and accrual of loss contingencies in respect of litigation and other claims. The Company records an accrual for a potential loss when it is probable that a loss will occur and the amount of the loss can be reasonably estimated. When the reasonable estimate of the potential loss is within a range of amounts, the minimum of the range of potential loss is accrued, unless a higher amount within the range is a better estimate than any other amount within the range. Moreover, even if an accrual is not required, the Company provides additional disclosure related to litigation and other claims when it is reasonably possible (i.e., more than remote) that the outcomes of such litigation and other claims include potential material adverse impacts on the Company. Legal costs to be incurred in connection with a loss contingency are expensed as such costs are incurred.

Table of Contents

Use of Estimates

The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates. Items subject to significant estimates and assumptions include the allowance for credit losses,

Table of Contents

loss contingencies, share-based compensations, useful lives and realizability of long-lived assets, deferred revenue and revenue recognition related to breakage, deferred franchise costs, calculation of ROU assets and liabilities related to leases, realizability of deferred tax assets, impairment of goodwill, impairment of intangible assets, impairment of other long-lived assets and purchase price allocations and related valuations.

Recent Accounting Pronouncements Adopted and Not Yet Adopted

In December 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires public entities to provide greater disaggregation within their annual rate reconciliation, including new requirements to present reconciling items on a gross basis in specified categories, disclose both percentages and dollar amounts and disaggregate individual reconciling items by jurisdiction and nature when the effect of the items meet a quantitative threshold. The guidance also requires disaggregating the annual disclosure of income taxes paid, net of refunds received, by federal (national), state and foreign taxes, with separate presentation of individual jurisdictions that meet a quantitative threshold. The guidance is effective for annual periods beginning after December 15, 2024 on a prospective basis, with a retrospective option, and early adoption is permitted. The Company ~~reviewed~~ newly is currently evaluating the impact of adoption of this standard on its consolidated financial statements and disclosures.

In November 2023, the FASB issued ~~accounting pronouncements~~ ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires public entities with a single reportable segment to provide all the disclosures required by this standard and ~~concluded~~ all existing segment disclosures in Topic 280 on an interim and annual basis, including new requirements to disclose significant segment expenses that ~~they either are not applicable~~ regularly provided to the ~~Company's~~ operations Chief Operating Decision Maker ("CODM") and included within the reported measure(s) of a segment's profit or that no material effect loss, the amount and composition of any other segment items, the title and position of the CODM and how the CODM uses the reported measure(s) of a segment's profit or loss to assess performance and decide how to allocate resources. The guidance is ~~expected~~ effective for annual periods beginning after December 15, 2023 and interim periods beginning after December 15, 2024, applied retrospectively with early adoption permitted. The Company is currently evaluating the impact of adoption of this standard on ~~the Company's~~ its consolidated financial statements ~~upon future adoption~~ and disclosures.

Note 2: Revenue Disclosures

Company-Owned or Managed Clinics

The Company earns revenues from clinics that it owns and operates or manages throughout the United States. Revenues are recognized when services are performed. The Company offers a variety of membership and wellness packages that feature discounted pricing as compared with its single-visit pricing. Amounts collected in advance for membership and wellness packages are recorded as deferred revenue and recognized when the service is performed or in accordance with the Company's breakage policy as discussed in Note 1, *Revenue Recognition*.

Franchising Fees, Royalty Fees, Advertising Fund Revenue and Software Fees

The Company currently franchises its concept across 41 states, the District of Columbia and Puerto Rico. The franchise arrangement is documented in the form of a franchise agreement. The franchise arrangement requires the Company to perform various activities to support the brand that do not directly transfer goods and services to the franchisee, but instead represent a single performance obligation, which is the transfer of the franchise license. The intellectual property subject to the franchise license is symbolic intellectual property as it does not have significant standalone functionality and substantially all of the utility is derived from its association with the Company's past or ongoing activities. The nature of the Company's promise in granting the franchise license is to provide the franchisee with access to the brand's symbolic intellectual property over the term of the license. The services provided by the Company are highly interrelated with the franchise license and as such are considered to represent a single performance obligation.

The transaction price in a standard franchise arrangement primarily consists of (a) initial franchise fees, (b) continuing franchise fees (royalties), (c) advertising fees, and (d) software fees. The revenue accounting standard provides an exception for the recognition of sales-based royalties promised in exchange for a license (which otherwise requires a reporting entity to estimate the amount of variable consideration to which it will be entitled in the transaction price).

[Table of Contents](#)

The Company recognizes the primary components of the transaction price as follows:

- Initial and renewal franchise fees, as well as transfer fees, are recognized as revenue ratably on a straight-line basis over the term of the respective franchise agreement, commencing with the execution of the franchise, renewal or transfer agreement. As these fees are typically received in cash at or near the beginning of the contract term, the cash received is initially recorded as a contract liability until recognized as revenue over time.
- The Company is entitled to royalties and advertising fees based on a percentage of the ~~franchisee's~~ franchisee's gross sales as defined in the franchise agreement. Royalty and advertising revenue are recognized when the ~~franchisee's~~ franchisee's sales occur. Depending on timing within a fiscal period, the recognition of revenue results in either what is considered a contract asset (unbilled receivable) or, once billed, accounts receivable, on the balance sheet.
- The Company is entitled to a software fee, which is charged monthly. The Company recognizes revenue related to software fees ratably on a straight-line basis over the term of the franchise agreement.

In determining the amount and timing of revenue from contracts with customers, the Company exercises significant judgment with respect to collectability of the amount; however, the timing of recognition does not require significant judgment as it is based on either the franchise term or the reported sales of the franchisee, none of which require estimation. The Company believes its franchising arrangements do not contain a significant financing component.

The Company recognizes advertising fees received under franchise agreements as advertising fund revenue.

[Table of Contents](#)

Capitalized Sales Commissions

Sales commissions earned by the regional developers and the Company's sales force are considered incremental and recoverable costs of obtaining a franchise agreement with a franchisee. These costs are deferred and then amortized as the respective franchise fees are recognized ratably on a straight-line basis over the term of the franchise agreement.

Disaggregation of Revenue

The Company believes that the captions contained on the condensed consolidated income statements appropriately reflect the disaggregation of its revenue by major type for the three and nine months ended **September 30, 2023** **March 31, 2024** and **2022** **2023**. Other revenues primarily consist of preferred vendor royalties associated with franchisees' credit card transactions.

The following table shows the Company's revenues disaggregated according to the timing of transfer of services:

	Three Months Ended		Nine Months Ended			
	September 30, 2023		September 30, 2023			
	2023	2022	2023	2022		
Three Months Ended						
March 31,						
2024			2024		Three Months Ended March 31,	
					2023	
Revenue	Revenue	\$27,418,343	\$24,697,661	\$81,155,737	\$68,436,945	
recognized	recognized					
at a point	at a point					
in time	in time					
Revenue recognized						
at a point in time						
Revenue recognized						
at a point in time						
Revenue	Revenue	2,055,606	1,752,158	5,926,216	5,136,988	
recognized	recognized					
over time	over time					
Total Revenues		\$29,473,949	\$26,449,819	\$87,081,953	\$73,573,933	
Total						
Revenue						

Rollforward of Contract Liabilities and Contract Assets

Changes in the Company's contract liability for deferred revenue from company clinics during the nine three months ended **September 30, 2023** **March 31, 2024** were as follows:

	Deferred Revenue from company clinics
Balance at December 31, 2022 December 31, 2023	\$ 7,471,549 4,463,747
Revenue recognized that was included in the contract liability at the beginning of the year	(5,959,308) (2,948,839)
Net increase during the nine months ended September 30, 2023 quarter ending March 31, 2024	5,026,472 3,088,694
Balance at September 30, 2023 March 31, 2024	<u><u>\$ 6,538,713 4,603,602</u></u>

[Table of Contents](#)

Changes in the Company's contract liability for deferred franchise fees during the **nine** **three** months ended **September 30, 2023** **March 31, 2024** were as follows:

	Deferred Revenue short and long-term
Balance at December 31, 2022 December 31, 2023	\$ 16,629,735 16,113,879
Revenue recognized that was included in the contract liability at the beginning of the year	(2,042,823) (650,383)
Net increase during the nine three months ended September 30, 2023 March 31, 2024	1,906,196 381,947
Balance at September 30, 2023 March 31, 2024	\$ 16,493,108 15,845,443

Table of Contents

The Company's deferred franchise and development costs represent capitalized sales commissions. Changes during the **nine** **three** months ended **September 30, 2023** **March 31, 2024** were as follows:

	Deferred Franchise and Development Costs short and long-term
Balance at December 31, 2022 December 31, 2023	\$ 6,761,738 6,251,366
Cost Recognized as cost of revenue recognized that was included in during the contract asset at the beginning of the year three months ended March 31, 2024	(863,619) (272,144)
Net increase during the nine three months ended September 30, 2022 March 31, 2024	566,339 83,578
Balance at September 30, 2023 March 31, 2024	\$ 6,464,458 6,062,800

The following table illustrates estimated revenues expected to be recognized in the future related to performance obligations that were unsatisfied (or partially unsatisfied) as of **September 30, 2023** **March 31, 2024**:

Amount		Amount
Contract	Contract	
liabilities	liabilities	
expected	expected	
to be	to be	
recognized	recognized	
in	in	Amount
2023 (remainder)		\$ 643,492
2024		2,495,683
2024 (remainder)		
2024 (remainder)		
2024 (remainder)		
2025	2025	2,358,322
2026	2026	2,264,085
2027	2027	2,190,960
2028		
Thereafter	Thereafter	6,540,566
Total	Total	\$16,493,108

Note 3: Acquisitions and Assets Held for Sale

2023 Acquisition

On May 22, 2023, the Company entered into an Asset and Franchise Purchase Agreement under which the Company repurchased from the sellers three operating franchised clinics in California (the "CA Clinics Purchase"). As of the acquisition date, the Company operates the franchises as company-managed clinics. The total purchase price for the transaction was \$1,188,764 to the seller (of which \$109,767 is to be paid in the fourth quarter of 2023), less \$28,997 of net deferred revenue, resulting in total purchase consideration of \$1,159,767.

Based on the terms of the purchase agreement, the CA Clinics Purchase has been treated as an asset purchase under GAAP as there were no outputs or processes to generate outputs acquired as part of these transactions. Under an asset purchase, assets are recognized based on their cost to the acquiring entity. Cost is allocated to the individual assets

acquired or liabilities assumed based on their relative fair values and does not give rise to goodwill.

The allocation of the total purchase price of the CA Clinics Purchase was as follows:

Property and equipment	\$	313,995
Operating lease right-of-use asset		317,662
Intangible assets		1,004,513
Total assets acquired		1,636,170
Deferred revenue		(158,365)
Operating lease liability - current portion		(118,081)
Operating lease liability - net of current portion		(199,957)
Net purchase consideration	\$	1,159,767

Table of Contents

Intangible assets in the table above primarily consist of reacquired franchise rights of \$0.7 million amortized over their estimated useful lives of six to seven years, customer relationships of \$0.1 million amortized over an estimated useful life of two years and assembled workforce of \$0.2 million amortized over an estimated useful life of two years.

2022 Acquisitions

On May 19, 2022, the Company entered into an Asset and Franchise Purchase Agreement under which the Company repurchased from the seller four operating franchises in Arizona (the "May 19th Acquisition"). The Company operates the franchises as company-owned clinics. The total purchase price for the transaction was \$5,761,256, less \$70,484 of net deferred revenue, resulting in total purchase consideration of \$5,690,772.

On July 5, 2022, the Company entered into an Asset and Franchise Purchase Agreement under which the Company repurchased from the seller one operating franchise in Arizona (collectively, including the May 19th Acquisition, the "AZ Clinics Purchase"). The Company operates the franchise as a company-owned clinic. The total purchase price for the transaction was \$1,205,667, less \$13,241 of net deferred revenue, resulting in total purchase consideration of \$1,192,426.

Based on the terms of the purchase agreements, the AZ Clinics Purchase has been treated as a business combination under U.S. GAAP using the acquisition method of accounting, which requires that assets acquired and liabilities assumed be recorded at the date of acquisition at their respective fair values. Any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.

The allocation of the total purchase price of the AZ Clinics Purchase was as follows:

Property and equipment	\$	241,511
Operating lease right-of-use asset		912,937
Intangible assets		3,689,100
Total identifiable assets acquired		4,843,548
Goodwill		3,408,205
Deferred revenue		(455,317)
Operating lease liability - current portion		(128,516)
Operating lease liability - net of current portion		(784,722)
Net purchase consideration	\$	6,883,198

Intangible assets in the table above consist of re-acquired franchise rights of \$2,892,100 amortized over estimated useful lives of approximately four to eight years and customer relationships of \$797,000 amortized over estimated useful lives of two to three years. The fair value of re-acquired franchise rights are estimated using the multi-period excess earnings method. The multi-period excess earnings method model estimates revenues and cash flows derived from the primary asset and then deducts portions of the cash flow that can be attributed to supporting assets, such as assembled workforce and working capital that contributed to the generation of the cash flows. The resulting cash flow, which is attributable solely to the primary asset acquired, is then discounted at a rate of return commensurate with the risk of the asset to calculate a present value. Customer relationships are also calculated using the multi-period excess earnings method.

The valuation method involved the use of significant estimates and assumptions primarily related to forecasted revenue growth rates, gross margin, contributory asset charges, customer attrition rates and market-participant discount rates. These measures are based on significant Level 3 inputs not observable in the market. Key assumptions developed based on the Company's historical experience, future projections and comparable market data include future cash flows, long-term growth rates, attrition rates and discount rates.

Goodwill represents the excess of the purchase consideration over the fair value of the underlying acquired net tangible and intangible assets. The factors that contributed to the recognition of goodwill included synergies and benefits expected to be gained from leveraging the Company's existing operations and infrastructures, as well as the expected associated revenue and cash flow projections. Goodwill has been allocated to the Company's Corporate Clinics segment based on such expected benefits. Goodwill related to the acquisition is expected to be deductible for income tax purposes over 15 years. The Company completed the purchase price allocation during the fourth quarter of 2022.

Table of Contents

On July 29, 2022, the Company entered into Asset and Franchise Purchase Agreements under which the Company repurchased from the sellers three operating franchises in North Carolina (the "NC Clinics Purchase"). The Company operates the franchises as company-managed clinics. The total purchase price for the transactions was \$1,317,312, less \$31,647 of net deferred revenue, resulting in total purchase consideration of \$1,285,665.

Based on the terms of the purchase agreement, the NC Clinics Purchase has been treated as asset purchases under U.S. GAAP as there were no outputs or processes to generate outputs acquired as part of this transaction. Under an asset purchase, assets are recognized based on their cost to the acquiring entity. Cost is allocated to the individual assets acquired or liabilities assumed based on their relative fair values and does not give rise to goodwill.

The allocation of the purchase price for the NC Clinics Purchase was as follows:

Property and equipment	\$	142,395
Operating lease right-of-use asset		122,641
Intangible assets		1,299,607
Total identifiable assets acquired		1,564,643
Deferred revenue		(153,176)
Operating lease liability - current portion		(85,414)
Operating lease liability - net of current portion		(40,388)
Net purchase consideration	\$	1,285,665

Intangible assets in the table above consist of re-acquired franchise rights of \$546,033 amortized over estimated useful lives of approximately two to four years, customer relationships of \$426,489 amortized over estimated useful lives of approximately three to four years and assembled workforce of \$327,085 amortized over an estimated useful life of two years.

Pro Forma Results of Operations (Unaudited)

The following table summarizes selected unaudited pro forma consolidated income statements for the three and nine months ended September 30, 2023 and 2022 for the 2023 and 2022 acquisitions, as if the CA Clinics Purchase in 2023 and the NC Clinics Purchase in 2022 (which have been accounted for as an asset purchase) and the AZ Clinics Purchase in 2022 (which have been accounted for as a business combination) had all been completed on January 1, 2022.

	Three Months Ended		Nine Months Ended	
	September 30,		September 30,	
	2023	2022	2023	2022
Revenues, net	\$ 29,473,949	\$ 26,905,560	\$ 87,820,694	\$ 76,866,953
Net income	(703,681)	697,316	1,290,407	(491,325)

The pro forma financial information is presented for informational purposes only and is not indicative of the results of operations that would have been achieved if the purchases had taken place on January 1, 2022 or of results that may occur in the future. For 2022, this information includes actual data recorded in the Company's consolidated financial statements for the period subsequent to the date of the acquisition.

The Company's condensed consolidated income statements for the three and nine months ended September 30, 2023 include net revenue and net income, excluding corporate clinic segment overhead costs, of the acquired California clinics as follows:

Table of Contents

	Three Months Ended		Nine Months Ended	
	September 30,		September 30,	
	2023	2023	2023	2023
Revenues, net			\$ 375,625	\$ 544,344
Net income			41,847	80,936

Assets Held for Sale

In June 2023, the Company entered into negotiations initiated plans to sell one re-franchise the majority of its company-managed clinics in California to a franchisee for a total of \$0.1 million. The Company executed an LOI with the buyer in October 2023 and the sale is expected to close before the end of 2023, subject to the execution of the purchase agreement and other customary closing conditions contained in the purchase agreement. This transaction did not represent a major strategic shift for the Company, and, therefore, it does not meet the criteria to be classified as a discontinued operation. As a result, the results of this clinic will continue to be reported in the Company's operating results and in its Corporate Clinics segment until the sale is finalized. Effective with the designation as held for sale in June 2023, the Company discontinued recording depreciation on property and equipment, net and amortization of ROU assets for the clinic as required by GAAP. The Company also separately classified the related assets and liabilities of the clinics as held for sale in its September 30, 2023 condensed consolidated balance sheet.

During Q3 2023, the Company committed to a plan to sell specific corporate owned corporate-owned or managed clinics making with plans to retain a small portion of high-performing clinics. The clinics identified to re-franchise make up under 10% approximately 76% of the corporate corporate-owned or managed clinic portfolio with an estimated fair value of \$1.6 million. portfolio. The clinics are in varying stages of sales negotiations with all approximately 50% of them expected to close within one year. year with an estimated fair value of \$30.2 million at March 31, 2024. The clinics identified to commit to sell during Q3 2023 within one year did not represent a major strategic shift and therefore, they because the clinics identified to commit to sell within one year do not meet the criteria to be classified as involve exiting a discontinued operation. major line of business or exiting a major geographic area. As a result, the results of these clinics will continue to be reported in the Company's operating results and in its Corporate Clinics segment until the sales are each finalized. Effective with the designation as held for sale, in September 2023, the Company discontinued recording depreciation on property and equipment, net, amortization of intangible assets, net and amortization of ROU assets for the clinics as required by GAAP. The Company also separately classified the related assets and liabilities of the clinics as held for sale in its September 30, 2023 March 31, 2024 condensed consolidated balance sheet.

Long-lived assets that meet the criteria for the held for sale designation are reported at the lower of their carrying value or fair value less estimated cost to sell. As a result of its evaluation of the recoverability of the carrying value of the assets and liabilities held for sale relative to the agreed upon sales prices or the clinics estimated fair values, the Company recorded an estimated loss

[Table of Contents](#)

on disposal of \$756,228 and \$816,429 during \$0.2 million for the three and nine months ended September 30, 2023 March 31, 2024 as Net loss on disposition or impairment in its condensed consolidated income statement and statement.

During the first quarter of 2024, in connection with the sale of a valuation allowance included in assets company-managed clinic classified as held for sale on its as of December 31, 2023, the Company sold \$0.2 million Assets held for sale, net of a \$0.1 million valuation allowance and \$0.1 million of Liabilities to be disposed of in the condensed consolidated balance sheet sheet as of March 31, 2024.

The principal components of the held for sale assets and liabilities as of September 30, 2023 December 31, 2023 and March 31, 2024 were as follows:

September 30, 2023		
Assets		
Property and equipment, net	\$ 2,153,454	
Operating lease right-of-use asset	2,204,293	
Intangible assets, net	386,280	
Goodwill	44,515	
Valuation allowance	(816,429)	
Total assets held for sale	\$ 3,972,113	
Liabilities		
Operating lease liability, current and non-current	\$ 2,585,642	
Deferred revenue from company clinics	386,291	
Total liabilities to be disposed of	\$ 2,971,933	

	March 31, 2024	December 31, 2023
Assets		
Property and equipment, net	\$ 4,616,181	\$ 4,887,220
Operating lease right-of-use asset	9,221,671	9,193,496
Intangible assets, net	3,351,430	3,351,430
Goodwill	1,266,707	1,140,529
Valuation allowance	(729,751)	(657,620)
Total assets held for sale	\$ 17,726,238	\$ 17,915,055

<u>Liabilities</u>			
Operating lease liability, current and non-current		\$ 9,168,048	\$ 10,209,382
Deferred revenue from company clinics		3,664,938	3,622,481
Total liabilities to be disposed of		\$ 12,832,986	\$ 13,831,863

Table The pre-tax income of **Contents** the clinics designated as held for sale was \$1.2 million and \$1.1 million for the three months ended March 31, 2024 and 2023, respectively, the results of which exclude the allocation of overhead.

Note 4: Property and Equipment

Property and equipment consisted of the following, excluding amounts related to properties classified as held for sale: following:

	September 30, 2023	December 31, 2022	March 31, 2024	March 31, 2024	December 31, 2023
Office and computer equipment	Office and computer equipment	\$ 5,693,432	\$ 5,207,833		
Leasehold improvements	Leasehold improvements	18,625,522	17,842,901		
Software developed	Software developed	6,048,742	5,843,758		
Finance lease assets	Finance lease assets	151,396	151,396		
		30,519,092	29,045,888		
		22,297,311			
Accumulated depreciation and amortization	Accumulated depreciation and amortization	(16,206,966)	(12,675,085)		
		14,312,126	16,370,803		
		9,437,212			
Construction in progress	Construction in progress	1,043,629	1,104,349		
Property and equipment, net	Property and equipment, net	\$15,355,755	\$17,475,152		

Depreciation expense was \$1,381,170 \$949,136 and \$1,046,495 \$1,270,260 for the three months ended September 30, 2023 March 31, 2024 and 2022, respectively. Depreciation expense was \$4,027,906 and \$2,866,737 for the nine months ended September 30, 2023 and 2022, 2023, respectively.

Amortization expense related to finance lease assets was \$7,570 and \$7,570 for the three months ended September 30, 2023 March 31, 2024 and 2022, respectively. Amortization expense related to finance lease assets was \$22,709 and \$48,001 for the nine months ended September 30, 2023 and 2022, 2023, respectively.

Construction in progress at September 30, 2023 March 31, 2024 and December 31, 2022 December 31, 2023 principally relates to development and construction costs for the company-owned Company-owned or managed clinics.

Note 5: Fair Value Measurements

Table of Contents

The Company's financial instruments include cash, restricted cash, accounts receivable, accounts payable, accrued expenses and debt under the Credit Agreement (defined as defined in Note 7, *Debt*). The carrying amounts of its financial instruments, except for debt, approximate their fair value due to their short maturities, maturities, which is considered a Level 1 fair value measurement. The carrying value of the Company's Company's debt under the Credit Agreement approximates fair value due to its interest rate being calculated from observable quoted prices for similar instruments, which is considered a Level 2 fair value measurement.

Authoritative guidance defines fair value as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the measurement date. The guidance establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability, developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company's assumptions of what

market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken down into three levels based on reliability of the inputs as follows:

- Level 1: Observable inputs such as quoted prices in active markets;
- Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and
- Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

As of **September 30, 2023** **March 31, 2024** and **December 31, 2022** **December 31, 2023**, the Company did not have any financial instruments that were measured on a recurring basis as Level 1, 2 or 3.

The Company's non-financial assets, which primarily consist of goodwill, intangible assets, property, plant and equipment and operating lease right-of-use assets, are not required to be measured at fair value on a recurring basis, and instead are reported at

Table of Contents

their carrying amount. However, on a periodic basis whenever events or changes in circumstances indicate that their carrying amount may not be fully recoverable (and at least annually for goodwill), non-financial assets are assessed for impairment. If the fair value is determined to be lower than the carrying amount, an impairment charge is recorded to write down the asset to its fair value, which is considered Level 3 within the fair value hierarchy.

The assets and liabilities resulting from the Acquisitions (see Note 3, *Acquisitions and Assets Held for Sale*) were recorded at fair values on a nonrecurring basis and are considered Level 3 within the fair value hierarchy.

Long-lived assets that meet the held for sale criteria are reported at the lower of their carrying value or fair value, less estimated costs to sell. The estimated fair values of the company-owned or managed clinics classified as Held for Sale (see Note 3, *Acquisitions and Assets Held for Sale*) were recorded at fair values on a nonrecurring basis and are based upon Level 2 inputs, which include potential buyer agreed upon selling prices or Level 3 inputs, which include historical and future expected financial performance of the clinic and historical acquisition trends based on previous reacquired franchise clinic purchases. As a result, the Company recorded a valuation allowance of \$756,228 and \$816,429 to adjust the carrying value of the disposal group to fair value less cost to sell during the three and nine months ended September 30, 2023, respectively.

During the three and nine months ended September 30, 2022, an operating lease ROU asset related to a closed clinic with a total carrying amount of approximately \$250,000 was written down to zero. The associated operating lease liability had a life of 39 months as of September 30, 2022. However, the ROU asset was fully impaired due to the abandonment of the lease as of September 30, 2022. The Company considers the ROU asset as abandoned as it lacks the ability to sublease the underlying asset and obtain economic benefits. As a result, the Company recorded a noncash impairment loss of approximately \$250,000 during the three and nine months ended September 30, 2022.

During the three and nine months ended September 30, 2023, intangible assets related to a clinic planned for closure with a total carrying amount of approximately \$80,000 was written down to zero. The remaining life of the intangible assets related to the clinic extend through December 2025. However, the clinic is planned to close at the end of its lease term in November 2023. The Company considers the intangible assets fully impaired as the ability to obtain economic benefits in the remaining period the clinic will operate is unlikely. As a result, the Company recorded a noncash impairment loss of approximately \$80,000 during the three and nine months ended September 30, 2023.

In connection with the planned sale of certain company-owned and managed clinics, the Company reclassified \$2,153,454 of net property and equipment, \$386,280 of intangible assets, net, \$44,515 of goodwill and \$2,204,293 of ROU assets to Assets held for sale and reclassified \$2,585,642 of lease liability and \$386,291 of deferred revenue from Company clinics to Liabilities to be disposed of in the condensed balance sheet as of September 30, 2023. Long-lived assets that meet the held for sale criteria are reported at the lower of their carrying value or fair value, less estimated costs to sell. The estimated fair value of assets held for sale are based upon Level 2 inputs, which includes a potential buyer agreed upon selling price or Level 3 inputs, which include historical and future expected financial performance of the clinic and historical acquisition trends based on previous reacquired franchise clinic purchases. The fair value measurement of the assets held for sale was recorded as \$0.3 million based upon Level 2 inputs and \$29.9 million based upon Level 3 inputs. As a result, the Company maintains a valuation allowance of \$0.7 million to adjust the carrying value of the disposal group to fair value less cost to sell as of March 31, 2024.

The Company recorded an impairment loss of \$0.1 million included in the net loss, disposition and impairment on the condensed consolidated income statement for impairment of long-lived assets classified as held and used where the asset group was not determined to be recoverable. The asset group was determined to be the clinic level, as this is the lowest level for which identifiable cash flows are largely independent of the cash flows of other groups of assets and liabilities. The long lived assets fair values were determined by the following: Level 2 inputs where available, which included using a valuation multiple (e.g. price per square foot) based on observable prices for comparable long lived assets; and Level 3 inputs, which included the multiple earnings approach using the Company's historical earnings trend data, comparable historical asset sales by the Company and franchisees that were not exact matches, and (for calculating the fair value of intangible assets specifically) the Company's historical experience, future projections and comparable market data include future cash flows, long-term growth rates, attrition rates and discount rates. The carrying values of these asset groups impaired to their fair value included fixed assets of \$0.9 million that were written down to \$0.7 million determined by the Level 3 inputs discussed above.

No impairments of long-lived assets were recorded for the three months ended March 31, 2023.

Note 6: Intangible Assets

In May 2022, the Company recognized \$2.4 million and \$0.5 million of reacquired franchise rights and customer relationships, respectively, from the Acquisition (see Note 3, *Acquisitions and Assets Held for Sale*).

In May 2023, the Company recognized \$0.7 million, \$0.1 million and \$0.2 million of reacquired franchise rights, customer relationships and acquired workforce, respectively, from the Acquisition (see Note 3, *Acquisitions and Assets Held for Sale*).

[Table of Contents](#)

Intangible assets consisted of the following:

		As of September 30, 2023			As of March 31, 2024			As of March 31, 2024		
		Gross Carrying Amount	Net Accumulated Amortization	Net Carrying Value			Gross Carrying Amount	Accumulated Amortization	Net Carrying Value	
Intangible assets subject to amortization:	Intangible assets subject to amortization:									
Reacquired franchise rights	Reacquired franchise rights									
Reacquired franchise rights	Reacquired franchise rights	\$12,924,858	\$(6,069,013)	\$6,855,845						
Customer relationships	Customer relationships	4,306,684	(3,126,081)	1,180,603						
Assembled workforce	Assembled workforce	1,065,311	(478,644)	586,667						
		\$18,296,853	\$(9,673,738)	\$8,623,115						
		\$								
		As of December 31, 2022 (as restated)			As of December 31, 2023			As of December 31, 2023		
		Gross Carrying Amount	Net Accumulated Amortization	Net Carrying Value			Gross Carrying Amount	Accumulated Amortization	Net Carrying Value	
Intangible assets subject to amortization:	Intangible assets subject to amortization:									
Reacquired franchise rights	Reacquired franchise rights									
Reacquired franchise rights	Reacquired franchise rights	\$12,881,894	\$(4,755,286)	\$ 8,126,608						
Customer relationships	Customer relationships	4,330,365	(2,352,500)	1,977,865						
Assembled workforce	Assembled workforce	959,837	(136,015)	823,822						
		\$18,172,096	\$(7,243,801)	\$10,928,295						
		\$								

Amortization expense related to the Company's intangible assets was \$960,466 \$447,200 and \$725,859 \$937,225 for the three months ended September 30, 2023 March 31, 2024 and 2022, respectively. Amortization expense was \$2,842,914 and \$1,663,712 for the nine months ended September 30, 2023 and 2022, 2023, respectively.

Estimated amortization expense for 2023 2024 and subsequent years is as follows:

Amount	
2023 (remainder)	\$ 901,345
2024	2,675,174
Amount	
2024 (remainder)	
2025	2025 1,602,969
2026	2026 1,272,426
2027	2027 717,394
2028	
Thereafter	Thereafter \$1,453,807
Total	Total \$8,623,115

Note 7: Debt

Credit Agreement

On February 28, 2020, the Company entered into a Credit Agreement (the "Credit Agreement"), with JPMorgan Chase Bank, N.A., individually and as Administrative Agent and Issuing Bank (the "Lender"). The Credit Agreement provided for senior secured credit facilities (the "Credit Facilities" "Credit Facilities") in the amount of \$7,500,000, including a \$2,000,000 revolver (the "Revolver") and \$5,500,000 development line of credit (the "Line of Credit"). The Revolver included amounts available for letters of credit of up to \$1,000,000 and an uncommitted additional amount of \$2,500,000. All outstanding principal and interest on the Revolver were due on February 28, 2022.

On February 28, 2022, the Company entered into an amendment to its Credit Facilities (as amended, the "2022 Credit Facility") with the Lender. Under the 2022 Credit Facility, the Revolver increased to \$20,000,000 (from \$2,000,000), the portion of the Revolver available for letters of credit increased to \$5,000,000 (from \$1,000,000), the uncommitted additional amount increased to \$30,000,000 (from \$2,500,000) and the developmental line of credit of \$5,500,000 was terminated. The Revolver will be used for working capital needs, general corporate purposes and for acquisitions, development and capital improvement uses. At the option of the Company, borrowings under the 2022 Credit Facility bear interest at (i) the adjusted SOFR rate, plus 0.10%, plus

Table of Contents

1.75%, payable on the last day of the selected interest period of one, three or six months and on the three-month anniversary of the beginning of any six month six-month interest period, if applicable; or (ii) an Alternative Base Rate (ABR), plus 1.00%, payable

Table of Contents

monthly. The ABR is the greatest of (A) the prime rate (as published by the Wall Street Journal); (B) the Federal Reserve Bank of New York rate, plus 0.5%; and (C) the adjusted one-month term SOFR rate. Amounts outstanding under the Revolver on February 28, 2022 continued to bear interest at the rate selected under the Credit Facilities prior to the amendment until the last day of the interest period in effect, at which time, if not repaid, the amounts outstanding under the Revolver will bear interest at the 2022 Credit Facility rate. As a result of this refinance, \$2,000,000 of current maturity of long-term debt was reclassified to long-term as of December 31, 2021. The 2022 Credit Facility will terminate and all principal and interest will become due and payable on the fifth anniversary of the amendment, (February 28, 2027) which will occur on February 28, 2027. On January 17, 2024, the Company paid down the outstanding balance on its Debt under the Credit Agreement of \$2,000,000.

The Credit Facilities contain customary events of default, including but not limited to nonpayment; material inaccuracy of representations and warranties, warranties; violations of covenants, covenants; certain bankruptcies and liquidations, liquidations; cross-default to material indebtedness, indebtedness; certain material judgments judgments; and certain fundamental changes such as a merger or sale of substantially all assets (as further defined in the Credit Facilities). The Credit Facilities require the Company to comply with customary affirmative, negative and financial covenants, including minimum interest coverage and maximum net leverage. A breach of any of these operating or financial covenants would result in a default under the Credit Facilities. If an event of default occurs and is continuing, the lenders could elect to declare all amounts then outstanding, together with accrued interest, to be immediately due and payable. The Credit Facilities are collateralized by substantially all of the Company's assets, including the assets in the Company's company-owned or managed clinics. The interest rate on funds borrowed under the Revolver as of September 30, 2023 was 7.09%. As of September 30, 2023 March 31, 2024, the Company was in compliance with all applicable financial and non-financial covenants under the Credit Agreement and \$2,000,000 remains there is no outstanding balance as of September 30, 2023 March 31, 2024.

Note 8: Stock-Based Compensation

The Company grants stock-based awards under its Amended and Restated 2014 Incentive Stock Plan (the "2014 Plan"). The shares issued as a result of stock-based compensation transactions generally have been funded with the issuance of new shares of the Company's common stock. The Company may grant the following types of incentive

awards under the 2014 Plan: (i) non-qualified stock options; (ii) incentive stock options; (iii) stock appreciation rights; (iv) restricted stock; and (v) restricted stock units. Each award granted under the 2014 Plan is subject to an award agreement that incorporates, as applicable, the exercise price, the term of the award, the periods of restriction, the number of shares to which the award pertains and such other terms and conditions as the plan committee determines. Awards granted under the 2014 Plan are classified as equity awards, which are recorded in stockholders' equity in the Company's consolidated balance sheets. Through **September 30, 2023** **March 31, 2024**, the Company has granted under the 2014 Plan (i) non-qualified stock options; (ii) incentive stock options; and (iii) restricted stock. There were no stock appreciation rights and restricted stock units granted under the 2014 Plan as of **September 30, 2023** **March 31, 2024**.

Stock Options

The Company's closing price on the date of grant is the basis of fair value of its common stock used in determining the value of share-based awards. To the extent the value of the Company's share-based awards involves a measure of volatility, the Company uses available historical volatility of the Company's common stock over a period of time corresponding to the expected stock option term. The Company historically has used the simplified method to calculate the expected term of stock option grants to employees as the Company did not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term of stock options granted to employees. Accordingly, the expected life of the options granted is based on the average of the vesting term, which is generally four years and the contractual term, which is generally ten years. The Company will continue to evaluate the appropriateness of utilizing such method. The risk-free interest rate is based on United States Treasury yields in effect at the date of grant for periods corresponding to the expected stock option term. Forfeitures are estimated based on historical and forecasted turnover, which is approximately 5%.

The Company did not grant options during the three and nine months ended **September 30, 2023** **March 31, 2024** and March 31, 2023.

Table of Contents

The information below summarizes the stock option activity for the **nine** **three** months ended **September 30, 2023** **March 31, 2024**:

	Number of Shares	Weighted Average Exercise Price	Remaining Contractual Life (Years)
Outstanding at December 31, 2022	531,923	\$ 9.20	4.7
Granted	Granted	—	—
Exercised	Exercised	(25,623)	7.90
Exercised			
Forfeited			
Forfeited	Forfeited	(7,375)	28.58
Expired	Expired	(12,591)	13.07
Outstanding at September 30, 2023	486,334	\$ 8.88	3.9
Exercisable at September 30, 2023	453,194	\$ 7.29	3.7
Expired			
Outstanding at March 31, 2024			
Outstanding at March 31, 2024			

Outstanding at March 31, 2024	<u>484,280</u>	<u>\$ 8.77</u>	<u>3.4</u>
Exercisable at March 31, 2024	<u>476,734</u>	<u>\$ 8.14</u>	<u>3.3</u>

For the three months ended **September 30, 2023** **March 31, 2024** and **2022, 2023**, stock-based compensation expense for stock options was **\$85,366** **\$54,739** and **\$113,324**, respectively. For the nine months ended **September 30, 2023** and **2022**, stock-based compensation expense for stock options was **\$235,972** and **\$420,680**, **\$64,882**, respectively.

Restricted Stock

Restricted stock granted to employees generally vests in four equal annual installments, although on March 5, 2024 and on May 25, 2023, the Company granted 29,454 shares and 51,401 shares, respectively, of restricted stock as part of a special award to certain high performing employees that vest in one installment on the first anniversary of the grant. Restricted stock granted to non-employee directors typically vests in full one year after the date of grant.

The information below summarizes the restricted stock activity for the **nine** three months ended **September 30, 2023** **March 31, 2024**:

Restricted Stock Awards	Stock Awards	Shares	Weighted Average Value per Award	Restricted Stock Awards		Shares	Weighted Average Grant-Date Fair Value per Award
				Weighted Average Date Fair Value per Award	Grant-Date Fair Value per Award		
Non-vested at December 31, 2022		70,312	\$ 29.05				
Non-vested at December 31, 2023							
Granted	Granted	204,122	14.54				
Vested	Vested	(33,782)	21.95				
Forfeited	Forfeited	(6,010)	34.43				
Non-vested at September 30, 2023		234,642	\$ 18.88				
Non-vested at March 31, 2024							

For the three months ended **September 30, 2023** **March 31, 2024** and **2022, 2023**, stock-based compensation expense for restricted stock was **\$440,703** **\$438,656** and **\$192,491**, respectively. For the nine months ended **September 30, 2023** and **2022**, stock-based compensation expense for restricted stock was **\$973,324** and **\$548,882**, **\$201,328**, respectively.

Note 9: Income Taxes

During the three months ended **September 30, 2023** **March 31, 2024** and **2022**, the Company recorded income tax benefit of \$188,018 and \$24,015, respectively. During the nine months ended **September 30, 2023** and **2022, 2023**, the Company recorded income tax expense of **\$493,286** **\$178,927** and income tax benefit of **\$560,976**, **\$841,889**, respectively. The Company's effective tax rates differ from the federal statutory tax rate due to permanent differences, discrete items and state taxes. The Company's effective tax rate differs from the statutory rate for the **nine** three months ended **September 30, 2023** **March 31, 2024** primarily due to nondeductible meals and entertainment, change in valuation allowance, state taxes, and an increase in the Company's ERC refunds from the Internal Revenue Service. The overall deferred tax effect of the refund amount, net of the liability related consulting fees, is treated as a discrete item for the nine months ended **September 30, 2023**, to indefinite goodwill. The effective tax rate for the three months ended **September 30, 2023** and for the three and nine months ended **September 30, 2022** **March 31, 2023** differs from the statutory rate primarily due to the pre-tax income reported by The Joint without the VIEs, permanent differences and state taxes.

Note 10: Commitments and Contingencies

Leases

Table of Contents

The table below summarizes the components of lease expense and income statement location for the three and nine months ended **September 30, 2023** **March 31, 2024** and **2022, 2023**:

[Table of Contents](#)

		Line Item in the Company's Condensed Consolidated Income Statements					Line Item in the Company's Condensed Consolidated Income Statements		Three Months Ended March 31, 2024		Three Months Ended March 31, 2023	
		Consolidated Income Statements	Three Months Ended September 30, 2023	Three Months Ended September 30, 2022	Nine Months Ended September 30, 2023	Nine Months Ended September 30, 2022						
		Income	September	September	September	September						
		Statements	30, 2023	30, 2022	30, 2023	30, 2022						
Line Item in the Company's Condensed Consolidated Income Statements												
Finance lease costs:	Finance lease costs:											
	Amortization of assets											
	Amortization of assets											
Amortization of assets	Amortization and of assets	Depreciation amortization	\$ 7,570	\$ 7,570	\$ 22,709	\$ 48,001						
Interest on lease liabilities	Interest on lease liabilities	Other expense, net	760	1,015	2,473	3,564						
Total finance lease costs	Total finance lease costs		8,330	8,585	25,182	51,565						
Operating lease costs	Operating lease costs	General and administrative expenses	1,633,469	\$1,426,010	4,910,181	\$4,138,801						
Total lease costs	Total lease costs		\$1,641,799	\$1,434,595	\$4,935,363	\$4,190,366						

Supplemental information and balance sheet location related to leases (excluding amounts related to leases classified as held for sale) is as follows:

	September 30, 2023	December 31, 2022
Operating Leases:		
Operating lease right-of -use asset	\$19,803,896	\$20,587,199
Operating lease liability - current portion	\$5,392,944	\$5,295,830
Operating lease liability - net of current portion	17,200,146	18,672,719
Total operating lease liability	\$22,593,090	\$23,968,549
Finance Leases:		
Property and equipment, at cost	\$151,396	\$151,396
Less accumulated amortization	(110,362)	(87,652)
Property and equipment, net	\$41,034	\$63,744
Finance lease liability - current portion	25,223	24,433
Finance lease liability - net of current portion	44,490	63,507
Total finance lease liabilities	\$69,713	\$87,940
Weighted average remaining lease term (in years):		
Operating leases	5.1	5.4
Finance lease	2.6	3.4
Weighted average discount rate:		
Operating leases	5.1 %	4.8 %
Finance leases	4.3 %	4.3 %

[Table of Contents](#)

	March 31, 2024	December 31, 2023
Operating Leases:		
Operating lease right-of -use asset	\$12,214,619	\$12,413,221
Operating lease liability - current portion	\$3,750,477	\$3,756,328
Operating lease liability - net of current portion	10,606,889	10,914,997
Total operating lease liability	<u>\$14,357,366</u>	<u>\$14,671,325</u>
Finance Leases:		
Property and equipment, at cost	\$151,397	\$151,396
Less accumulated amortization	(125,501)	(117,932)
Property and equipment, net	<u>\$25,896</u>	<u>\$33,464</u>
Finance lease liability - current portion	25,763	25,491
Finance lease liability - net of current portion	31,471	38,016
Total finance lease liabilities	<u>\$57,234</u>	<u>\$63,507</u>
Weighted average remaining lease term (in years):		
Operating leases	4.7	4.8
Finance lease	2.1	2.4
Weighted average discount rate:		
Operating leases	5.5 %	5.4 %
Finance leases	4.3 %	4.3 %

Supplemental cash flow information related to leases is as follows:

	Nine Months Ended September 30, 2023	Nine Months Ended September 30, 2022	
	Three Months Ended March 31, 2024		Three Months Ended March 31, 2023
Cash paid for amounts included in measurement of liabilities:	Cash paid for amounts included in measurement of liabilities:		
Operating cash flows from operating leases			
Operating cash flows from operating leases			
Operating cash flows from operating leases	Operating cash flows from operating leases	\$5,263,092	\$4,309,229
Operating cash flows from finance leases	Operating cash flows from finance leases	2,473	3,564
Financing cash flows from finance leases	Financing cash flows from finance leases	18,227	43,907

Non-cash transactions:	Non-cash transactions:
ROU assets obtained in exchange for lease liabilities	ROU assets obtained in exchange for lease liabilities
Non-cash transactions:	
ROU assets obtained in exchange for lease liabilities	
Operating lease	
Operating lease	
Operating lease	Operating lease \$4,287,622 \$4,402,229
Finance lease	Finance lease — —

[Table of Contents](#)

Maturities of lease liabilities as of **September 30, 2023** were **March 31, 2024** are as follows:

	Operating Leases	Finance Lease
2023 (remainder)	\$ 1,633,006	\$ 6,900
2024	6,236,923	27,600
2024 (remainder)	Operating Leases	Operating Leases
2025	2025 5,592,674	27,600
2026	2026 3,979,181	11,500
2027	2027 3,099,193	—
2028		
Thereafter	Thereafter 5,193,199	—
Total lease payments	Total lease payments \$25,734,176	\$73,600
Less: Imputed interest	Less: Imputed interest (3,141,086)	(3,887)
Total lease obligations	Total lease obligations 22,593,090	69,713
Less: Current obligations	Less: Current obligations (5,392,944)	(25,223)
Long-term lease obligation	Long-term lease obligation \$17,200,146	\$44,490

All leases During the last quarter of 2023, the Company entered into one operating lease that has not yet commenced for a space to be used by the Company have commenced as Company's new corporate clinics. The lease is expected to result in additional ROU assets and liabilities of September 30, 2023 approximately \$0.6 million. The lease is expected to commence during the second or the third quarter of 2024, with a lease term of five to ten years.

Guarantee in Connection with the Sale of the Divested Business

In connection with the sale of a company-managed clinic in 2022, the Company guaranteed one future operating lease commitment assumed by the buyers. The Company is obligated to perform under the guarantee if the buyers fail to perform under the lease agreement at any time during the remainder of the lease agreement, which expires on May 31,

2027. At the date of sale, the undiscounted maximum potential future payments totaled \$247,296. As of **September 30, 2023** **March 31, 2024**, the undiscounted remaining lease payments under the agreement totaled **\$196,896**, **\$171,696**. The Company had not recorded a liability with respect to the guarantee obligation as of **September 30, 2023** **March 31, 2024**, as the Company concluded that payment under the lease guarantee was not probable.

Litigation

In the normal course of business, the Company is party to litigation and claims from time to time. The Company maintains insurance to cover certain litigation and claims.

Note 11: Segment Reporting

An operating segment is defined as a component of an enterprise for which discrete financial information is available and is reviewed regularly by the Chief Operating Decision Maker ("CODM") to evaluate performance and make operating decisions. The Company has identified its CODM as the Chief Executive Officer.

The Company has two operating business segments and one non-operating business segment. The Corporate Clinics segment is composed of the operating activities of the company-owned or managed clinics. As of **September 30, 2023** **March 31, 2024**, the Company operated or managed **136** **135** clinics under this segment. The Franchise Operations segment is composed of the operating activities of

Table of Contents

the franchise business unit. As of **September 30, 2023** **March 31, 2024**, the franchise system consisted of **778** **819** clinics in operation. Corporate is a non-operating segment that develops and implements strategic initiatives and supports the Company's two operating business segments by centralizing key administrative functions such as finance and treasury, information technology, insurance and risk management, legal and human resources. Corporate also provides the necessary administrative functions to support the Company as a publicly traded company. A portion of the expenses incurred by Corporate are allocated to the operating segments.

The following tables below present financial information for the Company's two operating business segments.

	Three Months Ended		Nine Months Ended	
	September 30,		September 30,	
	2023	2022	2023	2022
Revenues:				
Corporate clinics	\$ 17,882,303	\$ 15,836,327	\$ 52,813,098	\$ 42,936,298
Franchise operations	11,591,646	10,613,492	34,268,855	30,637,635
Total revenues	\$ 29,473,949	\$ 26,449,819	\$ 87,081,953	\$ 73,573,933
Depreciation and amortization:				
Corporate clinics	\$ 2,067,803	\$ 1,504,914	\$ 6,027,561	\$ 3,780,283
Franchise operations	190,867	189,426	597,557	549,161
Corporate administration	90,536	85,584	268,411	249,006
Total depreciation and amortization	\$ 2,349,206	\$ 1,779,924	\$ 6,893,529	\$ 4,578,450
Segment operating income (loss):				
Corporate clinics	\$ (931,366)	\$ (60,022)	\$ (1,331,630)	\$ 345,657
Franchise operations	5,139,006	5,195,558	13,913,150	11,606,763
Total segment operating income	\$ 4,207,640	\$ 5,135,536	\$ 12,581,520	\$ 11,952,420
Reconciliation of total segment operating income to consolidated earnings before income taxes:				
Total segment operating income	\$ 4,207,640	\$ 5,135,536	\$ 12,581,520	\$ 11,952,420
Unallocated corporate	(5,105,687)	(4,403,220)	(14,507,231)	(12,589,279)
Consolidated (loss) income from operations	(898,047)	732,316	(1,925,711)	(636,859)
Other income (expense), net	(6,244)	(25,235)	3,708,399	(60,668)
(Loss) income before income tax benefit	\$ (904,291)	\$ 707,081	\$ 1,782,688	\$ (697,527)
Segment assets:				
		September 30, 2023	December 31, 2022	
				(as restated)

Corporate clinics	\$ 54,861,935	\$ 56,008,234
Franchise operations	12,299,470	12,360,878
Total segment assets	67,161,405	68,369,112
Unallocated cash and cash equivalents	17,142,353	10,550,417
Unallocated property and equipment	708,471	915,216
Other unallocated assets	13,560,397	13,655,632
Total assets	\$ 98,572,626	\$ 93,490,377

segments:

[Table of Contents](#)

	Three Months Ended	
	March 31,	
	2024	2023
Revenues:		
Corporate clinics	\$ 17,537,504	\$ 17,127,957
Franchise operations	12,184,662	11,172,863
Total revenues	\$ 29,722,166	\$ 28,300,820
Depreciation and amortization:		
Corporate clinics	1,104,232	1,927,091
Franchise operations	219,250	198,974
Corporate administration	80,424	88,990
Total depreciation and amortization	\$ 1,403,906	\$ 2,215,055
Segment operating income (loss):		
Corporate clinics	\$ 1,486,910	\$ (422,053)
Franchise operations	5,337,948	4,541,899
Total segment operating income	\$ 6,824,858	\$ 4,119,846
Reconciliation of total segment operating income to consolidated earnings before income taxes:		
Total segment operating income	\$ 6,824,858	\$ 4,119,846
Unallocated corporate	(5,734,582)	(4,772,955)
Consolidated income (loss) from operations	1,090,276	(653,109)
Other income, net	35,630	3,821,162
Income before income tax benefit	\$ 1,125,906	\$ 3,168,053
	March 31, 2024	December 31, 2023
Segment assets:		
Corporate clinics	\$ 50,809,138	\$ 52,210,617
Franchise operations	11,928,759	10,521,582
Total segment assets	62,737,897	62,732,199
Unallocated cash and cash equivalents and restricted cash	19,666,842	19,214,292
Unallocated property and equipment	561,340	2,843,491
Other unallocated assets	2,717,475	2,360,877
Total assets	\$ 85,683,554	\$ 87,150,859

"Unallocated cash and cash equivalents and restricted cash" relates primarily to corporate cash and cash equivalents and restricted cash (see Note 1, *Nature of Operations and Summary of Significant Accounting Policies*), "unallocated" property and equipment" relates primarily to corporate fixed assets and "other unallocated assets" relates primarily to deposits, prepaid and other assets.

Note 12: Employee Retention Credit

The employee retention credit ("ERC" ("ERC"), as originally enacted through the Coronavirus Aid, Relief and Economic Security Act ("CARES Act") on March 27, 2020, is a refundable credit against certain employment taxes equal to 50% of the qualified wages an eligible employer paid to employees from March 17, 2020 to December 31, 2020. The Disaster Tax Relief Act, enacted on December 27, 2020,

Table of Contents

December 27, 2020, extended the ERC for qualified wages paid from January 1, 2021 to June 30, 2021 and the credit was increased to 70% of qualified wages an eligible employer paid to employees during the extended period. The American Rescue Plan Act of 2021, enacted on March 11, 2021, further extended the ERC through December 31, 2021.

In October 2022, the Company filed an application with the IRS Internal Revenue Service (the "IRS") for the ERC. Employers are eligible for the credit if they experienced full or partial suspension or modification of operations during any calendar quarter because of governmental orders due to the pandemic or a significant decline in gross receipts based on a comparison of quarterly revenue results for 2020 and/or 2021 with the comparable quarter in 2019. The Company's ERC application was equal to 70% of qualified wages paid to employees during the period from January 1, 2021 to June 30, 2021 for a maximum quarterly credit of \$7,000 per employee. In March 2023, the Company received notice and refunds from the IRS related to the overpayment of Federal Employment Tax plus interest in the amount of \$4.8 million related to the ERC application. The \$4.8 million ERC is subject to a 20% consulting fee. The Company's Company's eligibility remains subject to audit by the IRS for a period of five years.

Since there are no generally accepted accounting principles for for-profit business entities that receive government assistance that is not in the form of a loan, an income tax credit or revenue from a contract with a customer, we the Company determined the appropriate accounting treatment by analogy to other guidance. We The Company accounted for the ERC by analogy to International Accounting Standards ("IAS") 20, Accounting for Government Grants and Disclosure of Government Assistance, of International Financial Reporting Standards.

Under an IAS 20 analogy, a business entity would recognize the ERC on a systematic basis over the periods in which the entity recognizes the payroll expenses for which the grant (i.e., tax credit) is intended to compensate when there is reasonable assurance (i.e., it is probable) that the entity will comply with any conditions attached to the grant and the grant (i.e., tax credit) will be received.

We have The Company accounted for the \$3.8 million ERC, net of the consulting fee, for in the nine months ended September 30, 2023 first quarter of 2023 as other income on the Statement of Income when the Company was reasonably assured that the Company it met all requirements of the ERC and the grant would be received. The ERC refund is not taxable; however, the credit is subject to expense disallowance rules which increased income tax expense as a discrete item by \$0.9 million, \$0.9 million, net of the consulting expense deduction, for the nine three months ended September 30, 2023 March 31, 2023.

Note 13: Subsequent Events Related Party Transaction

In October 2023, the Company entered into two separate letters

Mr. Jefferson Gramm, Managing Partner of intent to sell two Bandera Partners LLC who is a beneficial holder of its company-owned or managed clinics that were part more than 5% of the 10% clinics identified for sale and classified as held for sale our outstanding common stock (approximately 27% as of September 30, 2023 for a combined total sales price of \$185,000. The sales are expected March 31, 2024) was appointed to close during the fourth quarter of 2023, subject to customary closing conditions.

On November 6, 2023, the Company discussed certain strategic initiatives of the Company with the Board of Directors effective as of January 2, 2024, to serve until the election and were authorized qualification of his successor at the 2024 Annual Meeting.

In December 2020, we sold two franchise licenses at \$39,900 and \$29,900 each (which reflects the \$10,000 multi-unit discount for the second license per the Franchise Disclosure Document) to initiate Marshall Gramm, who is a plan family member of Mr. Jefferson Gramm. In April 2020 and 2021, we sold two franchise licenses at \$39,900 and \$29,900 each (which reflects the \$10,000 multi-unit discount for the second license per the Franchise Disclosure Document), to re-franchise a franchisee of which Mr. Jefferson Gramm is a 50% co-partner in the majority business.

These transactions involved terms no less favorable to us than those that would have been obtained in the absence of its corporate-owned or managed clinics with plans to retain a small portion such affiliation. Although we have no way of high-performing clinics. Based on estimating the timing aggregate amount of franchise fees, royalties, advertising fund fees, IT related income and varied scope computer software fees that these franchisees will pay over the life of the initiative, franchise licenses, the Company franchisees affiliated with Mr. Gramm are subject to such fees under the same terms and conditions as all other franchisees. These franchisees affiliated with Mr. Gramm paid \$32,864 and \$27,724 in the three months ended March 31, 2024 and 2023, respectively, for such royalties and other fees.

In October 2020, Mr. Gramm loaned approximately \$370,000 to an unaffiliated franchisee that owns and operates one franchise clinic. The loan is unable to estimate not secured by the financial impact assets of the business and there are no foreclosure rights.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated interim financial statements and related notes included in this Quarterly Report on Form 10-Q and the audited consolidated financial statements and notes thereto as of and for the year ended December 31, 2022 December 31, 2023 and the related Management's Discussion and Analysis of Financial Condition and Results of Operations, both of which are contained in our Amended Annual Report on Form 10-K/A, 10-K.

Forward-Looking Statements

Table of Contents

This Quarterly Report on Form 10-Q, especially in this Management's Discussion and Analysis or MD&A, contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, which are subject to the "safe harbor" created by those sections. All statements, other than statements of historical facts, included or incorporated in this Form 10-Q could be deemed forward-looking statements, particularly statements about our plans, strategies and prospects under the heading "Business" and "Management's Discussion and Analysis of Financial Condition and Results of Operations." In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential," "continue," "intend," "seek," "strive," or the negative of these terms, "mission," "goal," "objective," or "strategy," or other comparable terminology. All forward-looking statements in this Form 10-Q are made based on our current expectations, forecasts, estimates and assumptions and involve risks, uncertainties and other factors that could cause results or events to differ materially from those expressed in the forward-looking statements. In evaluating these statements, you should specifically consider various factors, uncertainties and risks that could affect our future results or operations as described from time to time in our SEC reports, including those risks outlined under "Risk Factors." Factors which are contained in Part I, Item 1A of our Annual Report on Form 10-K/A 10-K for the year ended December 31, 2022, December 31, 2023 and in Part II, Item 1A of this or any subsequent quarterly reports on Form 10-Q. These factors, uncertainties and risks may cause our actual results to differ materially from any forward-looking statement set forth in this Form 10-Q. You should carefully consider the trends, risks and uncertainties described below and other information contained in the reports we file with or furnish to the SEC before making any investment decision with respect to our securities. We undertake no obligation to update or revise publicly any forward-looking statements, other than in accordance with legal and regulatory obligations. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by this cautionary statement.

The specific forward-looking statements in this Quarterly Report on Form 10-Q include the following:

- that we seek to be the leading provider of chiropractic care in the markets we serve and to become the most recognized brand in our industry through the rapid and focused expansion of chiropractic clinics in key markets throughout North America and potentially abroad;
- our belief that our monthly performance reports from our system and our clinics provide us with useful data with which to measure our include key performance indicators per clinic, including gross sales, comparable same-store sales growth, or "Comp Sales," number of new patients, conversion percentage and to measure our franchisees' and clinics' performance; membership attrition;
- our plan to re-franchise or sell the majority of our company-owned or managed clinics, which refined strategy will leverage our greatest strength - our capacity to grow through the sale build a franchise - to drive long-term growth for both our franchisees and development off additional franchisees, build upon our regional developer strategy and continue to expand our corporate clinic portfolio within clustered locations; The Joint as a public company;
- our belief that the strong results with respect to our franchise licenses sold and our regional developers reflects the power of the regional developer program to accelerate the number of clinics sold, and eventually opened across the country;
- our belief that we can accelerate the development of, and revenue generation from, company-owned or managed clinics through the accelerated development of greenfield units and the further selective acquisition of existing franchised clinics;
- our plan continue to seek to acquire existing franchised clinics that meet our criteria for demographics, site attractiveness, proximity to other clinics and additional suitability factors;
- our belief that The Joint has have a sound business concept which was further validated through its resiliency during the pandemic and will benefit from the fundamental changes taking place in the manner in which Americans access chiropractic care and their growing interest in seeking effective, affordable natural solutions for general wellness;
- our belief that these trends join with the preference we have seen among chiropractic doctors to reject the insurance-based model to produce a combination that benefits the consumer and the service provider alike, and our belief that these forces create an important opportunity to accelerate the growth of our network;

Table of Contents

- our belief that recent events that may impact our business include unfavorable global economic or political conditions, such as a resurgence of COVID-19, the Ukraine War, the Israel-Gaza conflict, labor shortages, and inflation and other cost increases;
- our anticipation that 2023 2024 will continue to be a volatile macroeconomic environment;
- our expectation belief that elevated levels we have created a robust framework for the re-franchising effort, organizing clinics into clusters, and generating comprehensive disclosure packets for marketing efficiency, and that we have received significant interest to date from our existing franchisees;
- our goal to generate significant processes that will provide us with value creating capital allocation opportunities, which opportunities could include, but are not limited to, reinvestment in the brand and related marketing, continued investment in our IT platforms, the repurchase of cost inflation will persist in 2023, although at lower levels than

experienced in 2022; RD territories, and/or a stock repurchase program;

[Table of Contents](#)

- our belief that our operating results may fluctuate significantly as a result of a variety of factors, including the timing of new clinic sales, openings, closures, markets in which they are contained and related expenses, general economic conditions, cost inflation, labor shortages, consumer confidence in the economy, consumer preferences, competitive factors, and disease epidemics and other health-related concerns, such as **resurgence of COVID-19; as the COVID-19 pandemic;**
- our belief that our existing cash and cash equivalents, our anticipated cash flows from operations and amounts available under our line of credit will be sufficient to fund our anticipated operating and investment needs for at least the next **twelve** 12 months;
- our belief that we have adequate capital resources and sufficient access to external financing sources to satisfy our current and reasonably anticipated requirements for funds to conduct our operations and meet other needs in the ordinary course of our business; **and**
- our expectation that for the remainder of **2023 that 2024**, we **will expect to use or redeploy** **redeloy** our cash resources to support our business within the context of prevailing market conditions, which, given the ongoing uncertainties described **above**, could rapidly and materially deteriorate or otherwise **change; change.**

Some of the important factors that could cause our actual results to differ materially from those projected in any forward-looking statements include, but are not limited to, the following:

- the nationwide labor shortage has negatively impacted our ability to recruit chiropractors and other qualified personnel, which may limit our growth strategy, and the measures we have taken in response to the labor shortage have reduced our net revenues;
- inflation **exacerbated by COVID-19 and the Ukraine War**, has led to increased labor costs and interest rates and may lead to reduced discretionary spending, all of which may negatively impact our business;
- the COVID-19 pandemic has caused significant disruption to our operations and may continue to impact our business, key financial and operating metrics, and results of operations in numerous ways that remain unpredictable; future widespread outbreaks of contagious disease could similarly disrupt our business;
- we may not be able to successfully implement our growth strategy if we or our franchisees are unable to locate and secure appropriate sites for clinic locations, obtain favorable lease terms, and attract patients to our clinics;
- we have limited experience operating company-owned or managed clinics in those geographic areas where we currently have few or no clinics, and we may not be able to duplicate the success of some of our franchisees;
- we may not be able to acquire operating clinics from existing franchisees or develop company-owned or managed clinics on attractive terms;**
- short-selling strategies and negative opinions posted on the internet may drive down the market price of our common stock and could result in class action lawsuits;
- we have **previously identified** material weaknesses in our internal controls over financial reporting and we may fail to remediate **future** material weaknesses in our internal controls over financial reporting or may otherwise be unable to maintain an

[Table of Contents](#)

effective system of internal control over financial reporting, which might negatively impact our ability to accurately report our financial results, prevent fraud, or maintain investor confidence;

- we may fail to successfully design and maintain our proprietary and third-party management information systems or implement new systems;
- we have restated our prior consolidated financial statements, which may lead to additional risks and uncertainties, including loss of investor confidence and negative impacts on our stock price;
- we may fail to properly maintain the integrity of our data or to strategically implement, upgrade or consolidate existing information systems;
- franchised clinic acquisitions that we make could disrupt our business and harm our financial condition if we cannot continue their operational success or successfully integrate them;**
- we may not be able to continue to sell franchises to qualified franchisees, and our franchisees may not succeed in developing profitable territories and clinics;

[Table of Contents](#)

- new clinics may not reach the point of profitability, and we may not be able to maintain or improve revenues and franchise fees from existing franchised clinics;
- the chiropractic industry is highly competitive, with many well-established independent competitors, which could prevent us from increasing our market share or result in reduction in our market share;
- state administrative actions and rulings regarding the corporate practice of chiropractic and prepayment of chiropractic services may jeopardize our business model;
- expected new federal regulations and state laws and regulations regarding joint employer responsibility could negatively impact the franchise business model, increasing our potential liability for employment law violations by our franchisees and the likelihood that we may be required to participate in collective bargaining with our franchisees' employees;
- an increased regulatory focus on the establishment of fair franchise practices could increase our risk of liability in disputes with franchisees and the risk of enforcement actions and penalties;
- adverse developments affecting institutions, including bank failures, could adversely affect our liquidity and financial performance;
- negative publicity or damage to our reputation, which could arise from concerns expressed by opponents of chiropractic and by chiropractors operating under traditional service models, could adversely impact our operations and financial position;
- our IT security systems and those of our third-party service providers (as recently experienced by one of our marketing vendors) may be breached, and we may face civil liability and public perception of our security measures could be diminished, either of which would negatively affect our ability to attract and retain patients;
- new SEC regulations governing disclosure about risk management, strategy and governance regarding cybersecurity risks and new requirements for reporting of cybersecurity incidents may increase our compliance costs;
- legislation, regulations, as well as new medical procedures and techniques, could reduce or eliminate our competitive advantages; and
- the delayed filing of one of our quarterly report reports has made us currently ineligible to use a registration statement on Form S-3 to register the offer and sale of securities, which could adversely affect our ability to raise future capital or complete acquisitions.

Additionally, there may be other risks that are otherwise described from time to time in the reports that we file with the SEC. Any forward-looking statements in this report Quarterly Report on Form 10-Q should be considered in light of various important factors, including the risks and uncertainties listed above, as well as others.

[Table of Contents](#)

Overview

Our principal business is to develop, own, operate, support and manage chiropractic clinics through direct ownership, management arrangements, franchising and regional developers throughout the United States.

We seek to be the leading provider of chiropractic care in the markets we serve and to become the most recognized brand in our industry through the rapid and focused expansion of chiropractic clinics in key markets throughout North America and potentially abroad.

Key Performance Measures. We receive monthly performance reports from our system and our clinics that include key performance indicators per clinic, including gross sales, comparable same-store sales growth, or "Comp Sales," number of new patients, conversion percentage and membership attrition. In addition, we review monthly reporting related to system-wide sales, clinic openings, clinic license sales, adjusted EBITDA and various earnings metrics in the aggregate and per clinic. We believe these indicators provide us with useful data with which to measure our performance and to measure our franchisees' and clinics' performance. Comp Sales include the sales from both company-owned or managed clinics and franchised clinics that in each case have been open at least 13 full months and exclude any clinics that have closed. System-wide sales include sales at all clinics, whether operated by us or by franchisees. While franchised clinic sales are not recorded as revenues by us, management believes

[Table of Contents](#)

the information is important in understanding the overall brand's financial performance, because these sales are the basis on which we calculate and record royalty fees and are indicative of the financial health of the franchisee base. Adjusted EBITDA consists of net income before interest, income taxes, depreciation and amortization, acquisition related expenses (which includes contract termination costs associated with reacquired regional developer rights), stock-based compensation expense, bargain purchase gain, and (gain) loss on disposition or impairment, costs related to restatement filings, restructuring costs and other income related to the ERC. There was no costs related to restatement filings or bargain purchase gain for the three and nine months ended September 30, 2023 March 31, 2024 and 2022, 2023.

Key Clinic Development Trends. As of September 30, 2023 March 31, 2024, we and our franchisees operated or managed 914954 clinics, of which 778819 were operated or managed by franchisees and 136135 were operated as company-owned or managed clinics. Of the 136135 company-owned or managed clinics, 65 were constructed and

developed by us, and 71 70 were acquired from franchisees.

Our current strategy is to grow through the sale and development of additional franchises, franchises. After evaluating options for improvement, during 2023 the board authorized management to initiate a plan to re-franchise or sell the majority of our company-owned or managed clinics. This refined strategy will leverage our greatest strength - our capacity to build upon a franchise - to drive long-term growth for both our regional developer strategy franchisees and continue The Joint as a public company. We have created a robust framework for the re-franchising effort, organizing clinics into clusters, and generating comprehensive disclosure packets for marketing efficiency. We have given initial preference to expand existing franchisees and have received significant interest to date. Our goal will be to generate significant processes that will provide us with value creating capital allocation opportunities. These opportunities could include, but are not limited to, reinvestment in the brand and related marketing, continued investment in our corporate clinic portfolio within clustered locations, IT platforms, the repurchase of RD territories, and/or a stock repurchase program.

The number of franchise licenses sold for the year ended December 31, 2022 December 31, 2023 was 75,55, compared with 156 75 and 121 156 licenses for the years ended December 31, 2021 December 31, 2022 and 2020, 2021, respectively. We ended the first nine three months of 2023 2024 with 17 regional developers who were responsible for 52% 27% of the 50 15 licenses sold during the period. This strong result reflects the power of the regional developer program to accelerate the number of clinics sold, and eventually opened, across the country.

In addition, we believe that we can accelerate the development of, and revenue generation from, company-owned or managed clinics through the accelerated development of greenfield units and the further selective acquisition of existing franchised clinics. We will seek to acquire existing franchised clinics that meet our criteria for demographics, site attractiveness, proximity to other clinics and additional suitability factors. During the quarter ended September 30, 2023, we opened two greenfield clinics, United States.

We believe that The Joint has we continue to have a sound business concept which was further validated through its resiliency during the pandemic and will benefit from the fundamental changes taking place in the manner in which Americans access chiropractic care and their growing interest in seeking effective, affordable natural solutions for general wellness. These trends join with the preference we have seen among chiropractic doctors to reject the insurance-based model to produce a combination that benefits the consumer and the service provider alike. We believe that these forces create an important opportunity to accelerate the growth of our network.

Recent Events

Recent events that may impact our business include unfavorable global economic or political conditions, such as a resurgence of COVID-19, the Ukraine War, the Israel-Gaza conflict, labor shortages, and inflation and other cost increases. We anticipate that 2023 2024 will continue to be a volatile macroeconomic environment. As of the date of this Quarterly Report on Form 10-Q, we have not experienced a significant negative impact on our revenues and profitability due to the direct impact of the pandemic and the impact of Covid-19 in general as the business environment has largely moderated. However, there still remains uncertainty around the pandemic, including its effect on labor or other macroeconomic factors and the spread of new Covid-19 variants and resurgences.

The primary inflationary factor affecting our operations is labor costs. For the three In 2023 and nine months ended September 30, 2023, company-owned 2024, clinics owned or managed clinics by us were negatively impacted by labor shortages and wage increases, which increased our general and administrative expenses. Further, should we fail to continue to increase our wages competitively in response to

Table of Contents

increasing wage rates, the quality of our workforce could decline, causing our patient service to suffer. We expect elevated levels of cost inflation to persist in 2023, although at lower levels than experienced in 2022. While the effects of inflation on our labor costs have been we anticipate that these continued headwinds will be partially mitigated by pricing actions, we have taken in response, there can be no assurance that we will be able to continue to take such pricing actions. A continued increase in labor costs could have an adverse effect on our operating costs, financial condition and results of operations.

Also, the Ukraine War and the sanctions imposed on Russia in response to this conflict have increased global economic and political uncertainty. In addition, the increase in interest rates and the expectation that interest rates will continue to rise remain elevated may adversely affect patients' patients' financial conditions, resulting in reduced spending on our services. While the impact of these factors continues to remain uncertain, we will continue to evaluate the extent to which these factors will impact our business, financial condition, or results of operations. These and other uncertainties with respect to these recent events could result in changes to our current expectations.

Table of Contents

Other Significant Events and/or Recent Developments

For the three months ended September 30, 2023 March 31, 2024, compared to the prior year period:

- System-wide comp sales of clinics that have been open for at least 13 full months was flat, increased 3%.
- System-wide comp sales for mature clinics open 48 months or more decreased 5% 3%.

Table of Contents

- System-wide sales for all clinics open for any amount of time grew 8% increased 9%.

On November 6, 2023, the Company discussed certain strategic initiatives of the Company with the Board of Directors and were authorized to initiate a plan to re-franchise the majority of its corporate-owned or managed clinics with plans to retain a small portion of high-performing clinics. Based on the timing and varied scope of the initiative, the Company is unable to estimate the financial impact.

In October 2023, the Company entered into 2 separate letters of intent to sell 2 of its company-owned or managed clinics that were part of the 10% clinics identified for sale and classified as held for sale as of September 30, 2023 for a combined total sales price of \$185,000. The sales are expected to close during the fourth quarter of 2023, subject to customary closing conditions.

On June 15, 2023, we entered into an agreement under which we repurchased the right to develop franchises in various counties in Wisconsin. The total consideration for the transaction was \$1.0 million. We carried an upfront regional developer fee liability balance associated with this transaction of \$0.3 million, representing the unrecognized fee collected upon the execution of the regional developer agreement. We accounted for the termination of development rights associated with unsold or undeveloped franchises as a cancellation, and the associated upfront regional developer fee liability was netted against the aggregate purchase price. We recognized the net amount of \$0.7 million as a general and administrative expense on June 15, 2023.

On May 22, 2023, we entered into an Asset and Franchise Purchase Agreement under which we repurchased from the sellers three operating franchised clinics in California. We operate the franchises as company-managed clinics. The total purchase price for the transaction was \$1,188,764, less \$28,997 of net deferred revenue, resulting in total purchase consideration of \$1,159,767. Based on the terms of the purchase agreement, the acquisition has been treated as an asset purchase.

For the three months ended September 30, 2023, we constructed and developed two new corporate clinics.

Table of Contents

Factors Affecting Our Performance

Our operating results may fluctuate significantly as a result of a variety of factors, including the timing of new clinic sales, openings, closures, markets in which they are contained and related expenses, general economic conditions, cost inflation, labor shortages, consumer confidence in the economy, consumer preferences, competitive factors, and disease epidemics and other health-related concerns, such as a resurgence of COVID-19, the COVID-19 pandemic.

Critical Accounting Estimates

There were no changes in our critical accounting estimates during the **nine** **three** months ended **September 30, 2023** **March 31, 2024** from those set forth in "Significant Accounting Policies and Estimates" in our **Annual Report on Form 10-K/A 10-K** for the year ended **December 31, 2022** **December 31, 2023**.

Results of Operations

The following discussion and analysis of our financial results encompasses our consolidated results and results of our two business segments: Corporate Clinics and Franchise Operations.

Total Revenues ■ Three Months Ended September 30, 2023 March 31, 2024 Compared with Three Months Ended September 30, 2022 March 31, 2023

Components of revenues were as follows:

Revenues from company-owned or managed clinics	Revenues from company-owned or managed clinics	\$17,882,303	\$15,836,327	\$2,045,976	12.9 %	\$17,537,504	\$	\$17,127,957	\$	\$409,547	\$	2.4
Royalty fees	Royalty fees	7,143,791	6,604,653	539,138	8.2 %	Royalty fees	7,587,547	6,866,023	6,866,023	\$	\$	721,524
Franchise fees	Franchise fees	754,029	642,405	111,624	17.4 %	Franchise fees	655,873	754,425	754,425	\$	\$	(98,552)
Advertising fund revenue	Advertising fund revenue	2,050,106	1,881,367	168,739	9.0 %	Advertising fund revenue	2,166,473	1,952,406	1,952,406	\$	\$	214,067
IT related income and software fees	IT related income and software fees	1,301,577	1,109,753	191,824	17.3 %	IT related income and software fees	1,386,776	1,210,005	1,210,005	\$	\$	176,771
Other revenues	Other revenues	342,143	375,314	(33,171)	(8.8)%	Other revenues	387,993	390,004	390,004	\$	\$	(2,011)
Total revenues	Total revenues	\$29,473,949	\$26,449,819	\$3,024,130	11.4 %	Total revenues	\$29,722,166	\$	\$28,300,820	\$	\$	\$1,421,346

Consolidated Results

Total revenues increased by **\$3.0 million** **\$1.4 million**, primarily due to the continued expansion and revenue growth of our franchise base and the continued **expansion and revenue growth and expansion** of our company-owned or managed clinics portfolio.

Corporate Clinics

Revenues from company-owned or managed clinics increased, primarily due to the expansion of our company-owned or managed clinics portfolio. As of **September 30, 2023** **March 31, 2024** and **2022, 2023**, there were **136** **135** and **115** **130** company-owned or managed clinics in operation, respectively.

Franchise Operations

For the three months ended March 31, 2024, compared to the prior year period:

- Royalty fees and advertising fund revenue increased due to an increase in the number of franchised clinics in operation during the current period, along with continued sales growth in existing franchised clinics. As of **September 30, 2023** **March 31, 2024** and **2022, 2023**, there were **778** **819** and **690** **740** franchised clinics in operation, respectively.

Table of Contents

- Franchise fees **revenue increased** **decreased** due to the impact of **greater** accelerated revenue recognition resulting from the terminated franchise license agreements in the current quarter period compared to the prior period.

Table of Contents

- Software fees revenue increased due to an increase in our franchised clinic base and the related revenue recognition over the term of the franchise agreement as described above.
- Other revenues primarily consisted of merchant income associated with credit card transactions.

Total Revenues - Nine Months Ended September 30, 2023 Compared With Nine Months Ended September 30, 2022

Components of revenues were as follows:

Components of revenues were as follows:

	Nine Months Ended September 30,			Change from Prior Year	Percent Change from Prior Year
	2023	2022	(as restated)		
Revenues:					
Revenues from company-owned or managed clinics	\$ 52,813,098	\$ 42,936,298	\$ 9,876,800	23.0 %	
Royalty fees	21,181,973	19,024,799	2,157,174	11.3 %	
Franchise fees	2,179,822	1,970,256	209,566	10.6 %	
Advertising fund revenue	6,043,563	5,417,840	625,723	11.5 %	
IT related income and software fees	3,746,394	3,166,732	579,662	18.3 %	
Other revenues	1,117,103	1,058,008	59,095	5.6 %	
Total revenues	\$ 87,081,953	\$ 73,573,933	\$ 13,508,020	18.4 %	

Consolidated Results

Total revenues increased by \$13.5 million, primarily due to the continued expansion and revenue growth of our franchise base and of our company-owned or managed clinics portfolio.

Corporate Clinics

Revenues from company-owned or managed clinics increased, primarily due to improved same-store sales growth, as well as due to the expansion of our company-owned or managed clinics portfolio. As of September 30, 2023 and 2022, there were 136 and 115 company-owned or managed clinics in operation, respectively.

Franchise Operations

- Royalty fees and advertising fund revenue increased due to an increase in the number of franchised clinics in operation during the current period, along with continued sales growth in existing franchised clinics. As first quarter of September 30, 2023 and 2022, there 2023. There were 778 and 690 franchised clinics in operation, respectively.
- Franchise fees increased due to no such comparable events during the impact first quarter of greater accelerated revenue recognition resulting from the terminated franchise license agreements in the current year period compared to the prior period. 2024.
- Software fees revenue increased due to an increase in our franchised clinic base and the related revenue recognition over the term of the franchise agreement, as described above. in "Revenue Recognition" in Note 1, *Nature of Operations and Summary of Significant Accounting Policies*, to our condensed consolidated financial statements included in this Quarterly Report on Form 10-Q.
- Other revenues primarily consisted of merchant income associated with credit card transactions.

Table of Contents

Cost of Revenues				Change from Prior Year	Percent Change from Prior Year
	2023	2022	(as restated)		
Three Months Ended September 30,	\$ 2,604,100	\$ 2,337,095	\$ 267,005		11.4 %
Nine Months Ended September 30,	\$ 7,674,296	\$ 6,705,169	\$ 969,127		14.5 %
Three Months Ended March 31,	2024	2023	Change from Prior Year	Percent Change from Prior Year	
Cost of Revenues	\$ 2,716,076	\$ 2,474,685	\$ 241,391	9.8 %	

For the three months ended September 30, 2023 March 31, 2024, as compared with the three months ended September 30, 2022 March 31, 2023, the total cost of revenues increased primarily due to an increase in regional developer royalties and sales commissions of \$0.2 million. For the nine months ended September 30, 2023, as compared with the nine months ended September 30, 2022, the total cost of revenues increased, primarily due to an increase in regional developer royalties and sales commissions of \$0.8 million and a decrease in upfront regional developer contra cost of revenue expense of \$0.1 million. \$0.2 million.

Selling and Marketing Expenses

Selling and Marketing Expenses	2023	2022	Change from Prior Year	Percent Change from Prior Year
Three Months Ended September 30,	\$ 4,301,017	\$ 3,539,287	\$ 761,730	21.5 %
Nine Months Ended September 30,	\$ 13,169,079	\$ 10,666,500	\$ 2,502,579	23.5 %

Three Months Ended March 31,	2024	2023	Change from Prior Year	Percent Change from Prior Year
Selling and Marketing Expenses	\$ 3,886,113	\$ 4,160,244	\$ (274,131)	(6.6)%

Selling and marketing expenses increased/decreased for the three and nine months ended September 30, 2023/March 31, 2024, as compared to the three and nine months ended September 30, 2022/March 31, 2023, driven by an increase in advertising fund expenditures from by: (i) a larger franchise base and an increase/decrease in local marketing expenditures by the company-owned or managed clinics, clinics and (ii) the timing of the national marketing fund spend.

Depreciation and Amortization Expenses

Depreciation and Amortization Expenses	2023	2022	Change from Prior Year	Percent Change from Prior Year
		(as restated)		
Three Months Ended September 30,	\$ 2,349,206	\$ 1,779,924	\$ 569,282	32.0 %
Nine Months Ended September 30,	\$ 6,893,529	\$ 4,578,450	\$ 2,315,079	50.6 %

Three Months Ended March 31,	2024	2023	Change from Prior Year	Percent Change from Prior Year
Depreciation and Amortization Expenses	\$ 1,403,906	\$ 2,215,055	\$ (811,149)	(36.6)%

Depreciation and amortization expenses increased for the three and nine months ended September 30, 2023, as compared to the three and nine months ended September 30, 2022, primarily due to the depreciation expenses associated with the expansion of our company-owned or managed clinics portfolio in 2022 and 2023.

General and Administrative Expenses

General and Administrative Expenses	2023	2022	Change from Prior Year	Percent Change from Prior Year
		(as restated)		
Three Months Ended September 30,	\$ 20,212,750	\$ 17,796,806	\$ 2,415,944	13.6 %
Nine Months Ended September 30,	\$ 60,156,022	\$ 51,900,533	\$ 8,255,489	15.9 %

General and administrative expenses increased/decreased for the three months ended September 30, 2023/March 31, 2024, as compared to the three months ended September 30, 2022/March 31, 2023, primarily due to no depreciation and amortization expense recorded during the three months ended March 31, 2024 related to the assets held for sale at March 31, 2024.

General and Administrative Expenses

Three Months Ended March 31,	2024	2023	Change from Prior Year	Percent Change from Prior Year
General and Administrative Expenses	\$ 20,263,692	\$ 20,038,476	\$ 225,216	1.1 %

General and administrative expenses increased during the three months ended March 31, 2024 compared to the three months ended March 31, 2023, primarily due to restructuring costs of \$0.2 million and due to the increases in the following to support continued clinic count and revenue growth in both operating segments: (i) payroll and related expenses of \$1.5 million; \$0.5 million; and (ii) general overhead and administrative expenses of \$0.4 million; (iii) professional and advisory fees of \$0.3 million; and (iv) insurance costs \$0.5 million primarily related to increased audit fees. The increases were partially offset by a decrease of \$0.2 million. General and administrative expenses increased \$1.0 million in amortization of ROU assets for the nine clinics held for sale during the three months ended September 30, 2023, as compared to the nine months ended March 31, 2024.

Table of Contents

September 30, 2022, primarily due to the increases in the following to support continued clinic count and revenue growth in both operating segments: (i) payroll and related expenses of \$7.0 million; (ii) general overhead and administrative expenses of \$1.5 million; (iii) professional and advisory fees of \$0.4 million; (iv) software and maintenance costs of \$0.3 million; and (v) insurance costs of \$0.4 million, partially offset by the decrease in reacquiring regional developer upfront licensing fees of \$1.4 million. As a percentage of revenue, general and administrative expenses during the **three months ended September 30, 2023** **March 31, 2024** and **2022** **2023** were **69%** **68%** and **67%** **71%**, respectively.

Income (Loss) Income from Operations - Three Months Ended September 30, 2023 Compared With Three Months Ended September 30, 2022

Three Months Ended September 30,	2023	2022	Change from Prior Year		Percent Change from Prior Year
			(as restated)		
(Loss) Income from Operations	\$ (898,047)	\$ 732,316	\$ (1,630,363)		(222.6)%

Three Months Ended March 31,	2024	2023	Change from Prior Year		Percent Change from Prior Year
			(as restated)		
Income (Loss) from Operations	\$ 1,090,276	\$ (653,109)	\$ 1,743,385		(266.9)%

Consolidated Results

Consolidated income from operations **decreased** **increased** by **\$1.6 million** **\$1.7 million** for the three months ended **September 30, 2023** **March 31, 2024** compared with **the three months ended September 30, 2022** **March 31, 2023**, primarily due to **impairment recognized** the discontinued recording of depreciation on property and equipment, net, amortization of intangible assets, net and amortization of ROU assets for the clinics identified as held for sale and unallocated corporate segments discussed below, during the three months ended **March 31, 2024**, as required by GAAP.

Corporate Clinics

Our corporate clinics segment had **loss** **income** from operations of **\$0.9 million** **\$1.5 million** for the three months ended **September 30, 2023** **March 31, 2024**, a **decrease** **an increase** of **\$0.8 million** **\$1.9 million** compared to loss from operations of **\$0.1 million** for the three months ended **September 30, 2022**. An increase in revenues of **\$2.0 million** from company-owned or managed clinics was offset by a **\$0.8 million** increase to net loss on disposition or impairment due to certain corporate-owned or managed clinics being designated as held for sale and a **\$2.0 million** increase in operating expenses due to the increases in the following: (i) payroll-related expenses of **\$1.0 million** due to a higher head count to support the expansion of our corporate clinic portfolio and general wage increases to remain competitive in the current labor market; (ii) selling and marketing expenses of **\$0.4 million** driven by an increase in local marketing expenditures by the company-owned or managed clinics; and (iii) depreciation expense associated with the expansion of our company-owned or managed clinics portfolio of **\$0.6 million**.

Franchise Operations

Our franchise operations segment had income from operations of **\$5.1 million** for the three months ended **September 30, 2023**, a **decrease** of **\$0.1 million**, compared to income from operations of **\$5.2 million** for the prior year period. This increase was primarily due to:

- An increase of **\$0.3 million** in cost of revenues primarily due to an increase in regional developer royalties revenues of **\$0.4 million** from company-owned or managed clinics; and an increase
- a decrease of **\$0.8 million** **\$1.8 million** in operating expenses; expenses due to discontinued recording of depreciation on property and equipment, net, amortization of intangible assets, net and amortization of ROU assets for the clinics held for sale during the three months ended **March 31, 2024**; partially offset by
- An increase of **\$1.0 million** in total revenues.

Unallocated Corporate

Unallocated corporate expenses for the three months ended **September 30, 2023** increased by **\$0.7 million** compared to the prior year period, primarily due to the **an increase** in general and administrative expenses.

Loss from Operations - Nine months Ended September 30, 2023 Compared with Nine Months Ended September 30, 2022

Table **impairment loss** **of** **Contents**

Nine Months Ended September 30,	2023	2022	Change from Prior Year		Percent Change from Prior Year
			(as restated)		
Loss from Operations	\$ (1,925,711)	\$ (636,859)	\$ (1,288,852)		202.4 %

Consolidated Results

Consolidated loss from operations increased by \$1.3 million for the nine months ended September 30, 2023 compared with nine months ended September 30, 2022, primarily due to the increased expenses in the corporate clinics and unallocated corporate segments discussed below.

Corporate Clinics

Our corporate clinics segment had loss from operations of \$1.3 million for the nine months ended September 30, 2023, a decrease of \$1.6 million compared to income from operations of \$0.3 million for the prior year period. The decrease was primarily due to:

- A \$10.7 million increase in operating expenses due to the increases in the following: (i) payroll-related expenses of \$5.1 million due to a higher head count to support the expansion of our corporate clinic portfolio and general wage increases to remain competitive in the current labor market; (ii) depreciation expense associated with the expansion of our company-owned or managed clinics portfolio of \$2.2 million; (iii) selling and marketing expenses due to increased local marketing expenditures by the company-owned or managed clinics of \$1.8 million; and (iv) general overhead and administrative expenses to support the expansion of our corporate clinic portfolio of \$1.6 million; plus
- A \$0.8 million increase to net loss on disposition or impairment due to certain corporate-owned or managed clinics being designated as held for sale and; partially offset by
- An increase in revenues of \$9.9 million from company-owned or managed clinics, \$0.3 million.

Franchise Operations

Our franchise operations segment had income from operations of \$13.9 million \$5.3 million for the nine months ended September 30, 2023 March 31, 2024, an increase of \$2.3 million, \$0.8 million compared to income from operations of \$11.6 million \$4.5 million for the prior year period. This increase was primarily due to:

- An increase of \$3.6 million \$1.0 million in total revenues; partially offset by
- An increase of \$1.0 million \$0.2 million in cost of revenues primarily due to an increase in regional developer royalties and commissions and an increase of \$0.3 million in operating expenses. royalties.

Unallocated Corporate

Unallocated corporate expenses for the nine months ended September 30, 2023 March 31, 2024 increased by \$1.9 million \$1.0 million compared to the prior year period, primarily due to the increases in payroll related costs payroll-related expenses due to a higher head count to support the expansion of \$1.1 million, both operating segments and professional increases in audit and advisory accounting fees of \$0.4 million and insurance costs of \$0.4 million, to support the Company as a publicly traded company.

Other Income, (Expense), Net

Other Income (Expense), Net	2023	2022	Change from Prior Year	Percent Change from Prior Year
Three Months Ended September 30,	\$ (6,244)	\$ (25,235)	\$ 18,991	(75.3)%
Nine Months Ended September 30,	\$ 3,708,399	\$ (60,668)	\$ 3,769,067	(6,212.6)%

Table of Contents

Three Months Ended March 31,	2024	2023	Change from Prior Year	Percent Change from Prior Year
Other income, net	\$ 35,630	\$ 3,821,162	\$ (3,785,532)	99.1 %

Other income, (expense), net increased/decreased during the three months ended September 30, 2023 as March 31, 2024 compared to the three months ended September 30, 2022, primarily due to increased interest income. Other income (expense), net increased during the nine months ended September 30, 2023 as compared to the nine months ended September 30, 2022 March 31, 2023, primarily due to the recognition and receipt of the \$3.8 million of ERC, employee retention credits, net of the consulting fees, fee, in the first quarter of 2023. There were no such comparable events during the first quarter of 2024.

Table of Contents

Income Tax Expense

Three Months Ended March 31,	2024	2023	Change from Prior Year	Percent Change from Prior Year
Income tax expense	\$ 178,927	\$ 841,889	\$ (662,962)	78.7 %

Income tax expense decreased during the three months ended March 31, 2024 compared to the three months ended March 31, 2023, primarily due to decreased earnings before income tax expense and a change in the valuation allowance assessment as of December 31, 2023, at the Joint Corp.

Non-GAAP Financial Measures

The following table below reconciles net income to Adjusted EBITDA for the three and nine months ended September 30, 2023 March 31, 2024 and 2022 2023:

		Three Months Ended September 30,		Nine Months Ended September 30,					
		2023	2022	2023	2022				
		Three Months Ended March 31,							
		March 31,							
		2024	(as restated)		(as restated)	2024			
Non-GAAP	Non-GAAP								
Financial	Financial								
Data:	Data:								
Net income (loss)		\$ (716,273)	\$ 731,096	\$ 1,289,402	\$ (136,551)				
Non-GAAP Financial Data:									
Non-GAAP Financial Data:									
Net income									
Net income									
Net income									
Net interest expense	Net interest expense	6,244	25,235	70,905	60,668				
Depreciation and amortization expense	Depreciation and amortization expense	2,349,206	1,779,924	6,893,529	4,578,450				
Tax (benefit) expense		(188,018)	(24,015)	493,286	(560,976)				
Tax expense									
EBITDA	EBITDA	1,451,159	2,512,240	8,747,122	3,941,591				
Stock compensation expense	Stock compensation expense	526,069	305,815	1,209,296	969,562				
Acquisition related expenses	Acquisition related expenses	15,222	46,712	873,214	2,275,380				
Loss on disposition or impairment	Loss on disposition or impairment	904,923	264,391	1,114,738	360,140				
Other income related to the ERC		—	—	(3,779,304)	—				
Restructuring costs									
Other (income), net									
Adjusted EBITDA	Adjusted EBITDA	\$2,897,373	\$3,129,158	\$8,165,066	\$7,546,673				

Adjusted EBITDA consists of net income before interest, income taxes, depreciation and amortization, acquisition related expenses (which includes contract termination costs associated with reacquired regional developer rights), stock-based compensation expense, bargain purchase gain, and (gain) loss on disposition or impairment, costs related to restatement filings, restructuring costs, and other income related to the ERC. There was were no costs related to restatement filings or bargain purchase gain for the three and nine months ended September 30, 2023 March 31, 2024 and 2022, 2023. We have provided Adjusted EBITDA because it is a non-GAAP measure of financial performance commonly used for comparing companies in our industry. You should not consider Adjusted EBITDA as a substitute for operating profit or as an indicator of our operating performance or as an alternative to cash flows from operating activities as a measure of liquidity. We may calculate Adjusted EBITDA differently from other companies.

We believe that the use of Adjusted EBITDA provides an additional tool for investors to use in evaluating ongoing operating results and trends and in comparing our financial measures with other outpatient medical clinics, which may present similar non-GAAP financial measures to investors. In addition, you should be aware when evaluating Adjusted EBITDA that in the future we may incur expenses similar to those excluded when calculating these measures. Our presentation of these measures should not be construed as an inference that our future results will be unaffected by unusual or non-recurring items. Our computation of Adjusted EBITDA may not be comparable to other similarly titled measures computed by other companies, because all companies do not calculate Adjusted EBITDA in the same manner.

Liquidity and Capital Resources

As of **September 30, 2023** **March 31, 2024**, we had unrestricted cash and short-term bank deposits of **\$16.1 million** **\$18.7 million** and **\$18 million** **\$20 million** of available capacity under the **Revolver**, line of credit. While the pandemic, the Ukraine War and the Israel-Gaza conflict unfavorable global economic or political conditions create potential liquidity risks, as

[Table of Contents](#)

discussed further below, we believe that our existing cash and cash equivalents, our anticipated cash flows from operations, **our anticipated cash flows from investments as we execute our re-franchising strategy** and amounts available under our line of credit will be sufficient to fund our anticipated operating and investment needs for at least the next **twelve 12** months.

While the interruptions, delays and/or cost increases resulting from the pandemic, political instability or and geopolitical tensions, such as the Ukraine War and Israel-Gaza conflict, economic weakness, inflationary pressures, increase in interest rates and other factors have created uncertainty as to general economic conditions for **2023, 2024** and beyond, as of the date of this report, **Quarterly Report on Form 10-Q**, we believe we have adequate capital resources and sufficient access to external financing sources to satisfy our current and reasonably anticipated requirements for funds to conduct our operations and meet other needs in the ordinary course of our business. For the remainder

[Table of Contents](#)

of **2023, 2024**, we expect to use or redeploy our cash resources to support our business within the context of prevailing market conditions, which, given the ongoing uncertainties described above, could rapidly and materially deteriorate or otherwise change. Our long-term capital requirements primarily for acquisitions and other corporate initiatives, could be dependent on our ability to access additional funds through the debt and/or equity markets. If the equity or debt markets continue to deteriorate, or do not improve, including as a result of economic weakness, a resurgence of COVID-19, political unrest or war, including the Ukraine War and the Israel-Gaza conflict, or any other reason, it may make any necessary equity or debt financing more difficult to obtain in a timely manner and on favorable terms, if at all, and if obtained, it may be more costly or more dilutive. From time to time, we consider and evaluate transactions related to our portfolio and capital structure, including debt financings, equity issuances, purchases and sales of assets, and other transactions. **Given the ongoing uncertainties described above, the levels of our cash flows from operations for 2023 may be impacted.** There can be no assurance that we will be able to generate sufficient cash flows or obtain the capital necessary to meet our short and long-term capital requirements.

Analysis of Cash Flows

Net cash provided by operating activities **increased decreased by \$8.3 million** **\$3.2 million** to **\$11.3 million** **\$2.8 million** for the **nine three** months ended **September 30, 2023** **March 31, 2024**, compared to **\$3.0 million** **\$6.0 million** for the **nine three** months ended **September 30, 2022** **March 31, 2023**. The **increase decrease** was primarily attributable to recognizing the **\$3.9 million** ERC during the **Three** months ended **March 31, 2023**, which was partially offset by an increase in revenue over the prior year period, and the receipt of the **\$4.8 million** ERC, which was partially offset by an increase a decrease in general depreciation and administrative amortization expenses over the prior year period.

Net cash used in investing activities was **\$4.9 million** **\$0.3 million** and **\$12.3 million** **\$1.2 million** for the **nine three** months ended **September 30, 2023** **March 31, 2024** and **2022, 2023**, respectively. For the **nine three** months ended **September 30, 2023** **March 31, 2024**, this included acquisitions of **\$1.1 million** and purchases of property and equipment of **\$3.8 million** **\$0.4 million**. For the **nine three** months ended **September 30, 2022** **March 31, 2023**, this included acquisitions of **\$8.0 million** and the purchases of property and equipment of **\$4.3 million** **\$1.2 million**.

Net cash provided by used in financing activities for the **nine three** months ended **September 30, 2023** **March 31, 2024** was **\$0.2 million** **\$2.0 million**, compared to net cash provided by financing activities of **\$0.3 million** **\$0.1 million** for the **nine three** months ended **September 30, 2022** **March 31, 2023**. Net cash provided by financing activities was primarily driven from For the proceeds from the exercise of stock options for the **nine three** months ended **September 30, 2023** and **2022, March 31, 2024**, this included paying down the outstanding balance on its Debt under the Credit Agreement of **\$2.0 million**.

Recent Accounting Pronouncements

See Note 1, *Nature of Operations and Summary of Significant Accounting Policies*, to our condensed consolidated financial statements included in this **report** **Quarterly Report on Form 10-Q** for information regarding recently issued accounting pronouncements that may impact our financial statements.

Off-Balance Sheet Arrangements

During the **nine three** months ended **September 30, 2023** **March 31, 2024**, we did not have any relationships with unconsolidated organizations or financial partnerships, such as structured finance or special purpose entities that would have been established for the purpose of facilitating off-balance sheet arrangements.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

As of **September 30, 2023**, **March 31, 2024** there **were have been** no material changes to the quantitative and qualitative disclosures about market risk appearing in Part II, Item 7(a), "Quantitative and Qualitative Disclosures About Market Risk" of our **Annual Report on Form 10-K/A** **10-K** for the year ended **December 31, 2022** **December 31, 2023**.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our management evaluated the effectiveness of our disclosure controls and procedures as of **September 30, 2023****March 31, 2024**. The term "disclosure controls and procedures," as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and

[Table of Contents](#)

other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act are recorded, processed, summarized, and reported within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act are accumulated and communicated to the company's management, including its principal executive and principal

[Table of Contents](#)

financial officers, as appropriate to allow timely decisions regarding required disclosure. Our disclosure controls and procedures were designed to provide reasonable assurance of achieving such objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of **September 30, 2023****March 31, 2024**, our management concluded that, as of such date, our disclosure controls and procedures were not effective at the reasonable assurance level.

Our management determined that the material weaknesses disclosed for the year ended December 31, 2022 and 2021 in its internal control over financial reporting continue to exist at September 30, 2023, specifically we failed to properly design controls to appropriately determine the proper treatment of complex accounting areas, including income taxes, revenue recognition and asset acquisition transactions.

Remediation Plan for Existing Material Weaknesses

We are in the process of and continue to focus on implementing measures designed to ensure that control deficiencies contributing to the material weaknesses are remediated, such that these controls are designed, implemented and operating effectively. The remediation actions include modifying internal controls to address completeness of documentation on uncertain tax positions, revenue and acquisition related transactions and adoptions of the appropriate respective accounting standards, specifically through the utilization of subject matter experts to review conclusions over complex accounting policies. While we expect that our remediation actions over the design of our affected controls for the material weakness will be completed during fiscal 2023, the material weaknesses will not be considered remediated until the applicable controls operate for a sufficient period of time and management has concluded, through testing, that these controls are operating effectively.

Changes in Internal Control over Financial Reporting

Except as described above, there were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter three months ended **September 30, 2023****March 31, 2024** that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II: OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

In the normal course of business, we are a party to litigation from time to time. We maintain insurance to cover certain litigation and claims.

ITEM 1A. RISK FACTORS

We documented our risk factors in Item 1A of Part I of our **Annual Report on Form 10-K/A****10-K** for the year ended **December 31, 2022****December 31, 2023**. There have been no material changes to our risk factors since the filing of that report, except for the addition or modification of the following risk factors:

RISKS RELATED TO OPERATING OUR BUSINESS:

Inflation, exacerbated by COVID-19 and the Ukraine War, has led to increased labor costs and interest rates and may lead to reduced discretionary spending, all of which may negatively impact our business.

The primary inflationary factor affecting our operations is labor costs. During 2022 and 2023, company-owned or managed clinics were negatively impacted by wage increases, which increased our general and administrative expenses and decreased profitability. A significant number of our clinic service personnel are paid at rates related to the applicable minimum wage, and increases in the minimum wage could increase our labor costs. As of January 1, 2023, the minimum wage increased in a number of states, the District of Columbia and local municipalities, with many of these wage increases triggered automatically by increases in the cost of living due to high inflation. Such wage increases likely will further increase our general and administrative expenses in the affected jurisdictions. A continued increase in labor costs is likely to continue to have an adverse impact on profitability and may result in additional price increases to offset their impact. Further, should we fail to continue to increase our wages competitively in response to any continued increase in wage rates, the quality of our workforce could decline, causing our patient services to suffer.

In addition to relief and recovery, our services emphasize preventive and maintenance care, which is generally not a medical necessity, and may be viewed as a discretionary medical expenditure. Discretionary spending is negatively impacted by, among

Table of Contents

other things, those factors disclosed in our Form 10-K/A for the year ended December 31, 2022 under the caption "Recent Events" in Management's Discussion and Analysis of Financial Condition and Results of Operations -- unfavorable global economic or political conditions, such as the recent COVID-19 pandemic, the Ukraine War, inflation and other cost increases, and increases in interest rates. As further disclosed under the aforementioned caption, we anticipate that fiscal 2023 will continue to be a volatile macroeconomic environment and expect elevated levels of cost inflation to persist for 2023. Reductions in discretionary spending may adversely impact our business, financial condition, or results of operations. Rising interest rates also will make it more expensive for potential franchisees to finance new clinic acquisitions and thus may reduce the pool of available franchisees, which also could adversely impact our business. Borrowings under our credit facility bear interest at rates tied to certain benchmark interest rates. Increases in the federal funds rate has caused these benchmark rates to increase, and additional increases are likely to further increase such benchmark rates. Higher rates increase our borrowing costs and may reduce the amounts available under our credit facility for our corporate needs, including working capital, capital expenditures and acquisitions.

In the event that a further deterioration of economic conditions causes a significant decrease in demand for our services, this could negatively impact our ability to meet the financial covenants in our credit facility, although we were in compliance as of September 30, 2023. Furthermore, a deterioration of equity and credit markets may make other debt or equity financing difficult to obtain in a timely manner and on favorable terms, if at all, and if obtained, may be more costly or more dilutive. If we are unable to access our credit facility as a result of noncompliance with its covenants or are unable to obtain other debt or equity financing, this could limit our opportunity to acquire more clinics and regional developer rights and to pursue other corporate initiatives.

FINANCIAL RISK FACTORS:

We maintain cash deposits in banks in excess of federally insured limits. Adverse developments affecting financial institutions, including bank failures, could adversely affect our liquidity and financial performance.

We regularly maintain cash deposits in Federal Deposit Insurance Corporation ("FDIC") insured banks that exceed the FDIC insurance limits. Bank failures, events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, or concerns or rumors about such events, may lead to liquidity constraints. For example, on March 10, 2023, Silicon Valley Bank failed and was taken into receivership by the FDIC. Although we did not have any funds in Silicon Valley Bank or other institutions that have been closed, we cannot guarantee that the banks or other financial institutions that hold our funds will not experience similar issues. The failure of a bank, or other adverse conditions in the financial or credit markets impacting financial institutions at which we maintain balances, could adversely impact our liquidity and financial performance. There can be no assurance that our deposits in excess of the FDIC or other comparable insurance limits will be backstopped by the U.S., or that any bank or financial institution with which we do business will be able to obtain needed liquidity from other banks, government institutions or by acquisition in the event of a failure or liquidity crisis.

RISKS RELATED TO OTHER LEGAL AND REGULATORY MATTERS:

We conduct business in a heavily regulated industry, and if we fail to comply with these laws and government regulations, we could incur penalties or be required to make significant changes to our operations.

We, our franchisees and the chiropractor-owned PCs to which we and our franchisees provide management services are subject to extensive federal, state and local laws, rules and regulations, including the following: (i) federal and state laws governing the franchisor-franchisee relationship; (ii) state regulations on the practice of chiropractic; (iii) federal and state laws governing the collection, dissemination, use, security and confidentiality of sensitive personal information; (iv) federal and state laws which contain anti-kickback and fee-splitting provisions and restrictions on referrals; (v) the federal Fair Debt Collection Practices Act and similar state laws that restrict the methods that we and third-party collection companies may use to contact and seek payment from patients regarding past due accounts; (vi) prepayment for chiropractic services; and (vii) federal and state labor laws, including wage and hour laws.

Some state regulations concerning the practice of chiropractic could limit the use of our business model or certain of our business practices in certain states, which may make expanding into those states less attractive. For example, some states prohibit payment in advance for chiropractic services. This has the effect of limiting or prohibiting the use of our membership model in any such states, given that our membership model provides for the payment in advance of a monthly membership fee prior to receipt of services and without regard to whether services are actually provided. We recently elected not to offer franchises in South Dakota and Wyoming because of such a prohibition.

Table of Contents

Many of the above laws, rules and regulations applicable to us, our franchisees and our affiliated PCs are ambiguous, have not been definitively interpreted by courts or regulatory authorities and vary from jurisdiction to jurisdiction. Accordingly, we may not be able to predict how these laws and regulations will be interpreted or applied by courts and regulatory authorities, and some of our activities could be challenged. In addition, we must consistently monitor changes in the laws and regulations that govern our operations. Furthermore, a review of our business by judicial, law enforcement or regulatory authorities could result in a determination that could adversely affect our operations. Although we have tried to structure our business and contractual relationships in compliance with these laws, rules and regulations in all material respects, if any aspect of our operations were found to violate applicable laws, rules or regulations, we could be subject to significant fines or other penalties, required to cease operations in a particular jurisdiction, prevented from commencing operations in a particular state or otherwise be required to revise the structure of our business or legal arrangements. Our efforts to comply with these laws, rules and regulations may impose significant costs and burdens, and failure to comply with these laws, rules and regulations may result in fines or other charges being imposed on us.

RISKS RELATED TO INFORMATION TECHNOLOGY, CYBERSECURITY AND DATA PRIVACY:

New SEC regulations governing disclosure about risk management, strategy and governance regarding cybersecurity risks and new requirements for reporting of cybersecurity incidents may increase our compliance costs.

The SEC recently adopted a rule, "Cybersecurity Risk Management, Strategy, Governance, and Incident Disclosure," that enhances and standardizes disclosures regarding cybersecurity risk management and governance, as well as material cybersecurity incidents. Under this new rule, public companies will now be required to make annual disclosures describing their processes for identifying and managing material cybersecurity risks, management's role in assessing and managing such risks, and the Board of Directors' oversight of cybersecurity risks. Companies also must disclose in a Form 8-K the nature, scope and timing of any material cybersecurity incidents identified and the material impact or reasonably likely material impact on the company. We expect to face increased costs to comply with this new SEC cybersecurity rule, including increased costs for cybersecurity training and management. Furthermore, the requirement to report cybersecurity incidents within such a short time frame could mean that there will not be sufficient time to halt a breach before having to report it, potentially giving hackers an advantage. 10-K.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Use of Proceeds from Registered Securities

None.

ITEM 3.5. OTHER INFORMATION

During the quarter ended **September 30, 2023** **March 31, 2024**, no director or officer of our company adopted or terminated a "Rule 10b5-1 trading arrangement" or a "non-Rule 10b5-1 trading arrangement" (in each case, defined in Item 408 of Regulation S-K).

[Table of Contents](#)

ITEM 6. EXHIBITS

EXHIBIT INDEX

Exhibit Number	Description of Document
31.1*	Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, (filed herewith).
31.2*	Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, (filed herewith).
32**	Certifications of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith).
101.INS	XBRL Instance Document.
101.SCH	XBRL Taxonomy Extension Schema Document.
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB	XBRL Taxonomy Extension Label Linkbase Document.
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document.
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

* Filed herewith

** Furnished herewith, not filed

[Table of Contents](#)

THE JOINT CORP.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this **report** **Quarterly Report on Form 10-Q** to be signed on its behalf by the undersigned thereunto duly authorized.

THE JOINT CORP.

Dated: November 9, 2023 May 2, 2024

By: /s/ Peter D. Holt

Peter D. Holt
President and Chief Executive Officer
(Principal Executive Officer)

Dated: November 9, 2023 May 2, 2024

By: /s/ Jake Singleton

Jake Singleton
Chief Financial Officer
(Principal Financial Officer and Principal Accounting Officer)

4936

Exhibit 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
PURSUANT TO RULES 13a-14(a) AND 15a-14(a)
OF THE SECURITIES EXCHANGE ACT OF 1934

I, Peter D. Holt, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023 March 31, 2024 of The Joint Corp.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 9, 2023 May 2, 2024

/s/ Peter D. Holt

Peter D. Holt
President and Chief Executive Officer
(Principal Executive Officer)

**CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
PURSUANT TO RULES 13a-14(a) AND 15a-14(a)
OF THE SECURITIES EXCHANGE ACT OF 1934**

I, Jake Singleton, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended **September 30, 2023** **March 31, 2024** of The Joint Corp.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: **November 9, 2023** **May 2, 2024**

/s/ Jake Singleton

Jake Singleton
Chief Financial Officer
(Principal Financial Officer and Principal Accounting Officer)

**CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report on Form 10-Q of The Joint Corp. (the "Company"), for the quarter ended Date: **September 30, 2023** **March 31, 2024**, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), each of the undersigned hereby certifies, in his or her capacity as an officer of the Company, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to his knowledge:

- (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

By: /s/ Peter D. Holt

Peter D. Holt
President and Chief Executive Officer
(Principal Executive Officer)

Dated November 9, 2023 May 2, 2024

By: /s/ Jake Singleton

Jake Singleton
Chief Financial Officer
(Principal Financial Officer and Principal Accounting
Officer)

Dated November 9, 2023 May 2, 2024

DISCLAIMER

THE INFORMATION CONTAINED IN THE REFINITIV CORPORATE DISCLOSURES DELTA REPORT™ IS A COMPARISON OF TWO FINANCIALS PERIODIC REPORTS. THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORT INCLUDING THE TEXT AND THE COMPARISON DATA AND TABLES. IN NO WAY DOES REFINITIV OR THE APPLICABLE COMPANY ASSUME ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED IN THIS REPORT. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S ACTUAL SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.

©2024, Refinitiv. All rights reserved. Patents Pending.